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ABSTRACT 
 
Background. Diabetes mellitus (DM) increases cardiovascular disease (CVD) 
and this is attributed, at least in part, to shortage of vascular regenerative cells 
derived from the bone marrow (BM). Indeed, the BM harbours several subsets of 
progenitor cells for endothelial, smooth muscle cells and cardiomyocytes, which 
derive from a common CD34+ ancestor. Recent data from experimental models 
of type 1 and type 2 diabetes highlight BM pathologies that include 
microangiopathy, neuropathy, altered gene expression and niche dysfunction. 
Aims. The set of experiments herein described aim to portray the alterations of 
BM function in clinical and experimental diabetes. 
Methods. The approaches are diversified and include: 1) A prospective trial of 
direct BM stimulation with human recombinant granulocyte colony stimulating 
factor (G-CSF) in diabetic and non diabetic patients; 2) A meta-regression 
analysis of trials using G-CSF to stimulate cardiovascular repair in diabetic and 
non diabetic patients; 3) A study of stem/progenitor cell compartmentalization in 
the BM and peripheral blood (PB), in relation to diabetes; 4) An animal study to 
dissect the role of DPP-4 dysregulation in the impaired stem/progenitor cell 
mobilization induced by diabetes. 
Results. Part 1: in response to G-CSF, levels of CD34+ cells and other 
progenitor cell phenotypes increased in non DM subjects. DM patients had 
significantly impaired mobilization of CD34+, CD133+, CD34+CD133+ 
hematopoietic stem cells and CD133+KDR+ endothelial progenitors, 
independently of potential confounders. The in vivo angiogenic capacity of 
circulating mononuclear cells increased after hrG-CSF in non DM controls, but 
not in DM patients. DM was associated with inability to upregulate CD26/DPP-4 
on CD34+ cells, which is required for the mobilizing effect of G-CSF. 
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Part 2: for the meta-regression analysis 227 articles were screened, 96 were 
retrieved for evaluation and 24 retained for the analysis of the primary end-point. 
There was a strong negative correlation between prevalence of diabetes and 
achieved CD34+ cell levels after G-CSF stimulation (r=-0.68; p<0.0001), while 
there was no correlation with other traditional risk factors. A multiple regression 
analysis showed that the correlation between diabetes and mobilization was 
independent. In 13 articles reporting pre- and post-G-CSF cell counts, the 
increase in CD34+ cells was also negatively correlated with prevalence of 
diabetes (r=-0.82; p<0.0001).   
Part 3. PB and BM CD34+ cell counts were directly correlated, and that most 
circulating CD34+ cells were viable, non-proliferating and derived from the BM. 
Then, PB and BM CD34+ cell levels were analyzed in a 2-compartment model in 
72 patients with or without cardiovascular disease. Self organizing maps showed 
that disturbed compartmentalization of CD34+ cells was associated with aging 
and cardiovascular risk factors, especially diabetes. High activity of DPP-4, a 
regulator of the mobilizing chemokine SDF-1α, was associated with altered stem 
cell compartmentalization. The role of DPP-4 in the BM mobilization response of 
diabetic rats was then assessed. Diabetes differentially affected DPP-4 activity in 
PB and BM and impaired stem/progenitor cell mobilization after ischemia or G-
CSF administration. DPP-4 activity in the BM was required for the mobilizing 
effect of G-CSF, while in PB it blunted ischemia-induced mobilization. Indeed, 
DPP-4 deficiency restored ischemia (but not G-CSF) -induced stem cell 
mobilization and improved vascular recovery in diabetic animals. 
Conclusion. Evidences from multiple clinical and experimental approaches 
indicate that diabetes impairs the mobilization of stem/progenitor cells from the 
BM to PB. This primary BM defect is related to a maladaptive and tissue-specific 
DPP-4 dysregulation. 
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RIASSUNTO 
 
Presupposti. Il diabete mellito (DM) aumenta il rischio cardiovascolare e ciò 
viene attribuito almeno in parte alla riduzione delle cellule vasculo-rigenerative di 
origine midollare. Infatti il midollo osseo contiene precursori per cellule 
endoteliali, muscolari lisce e cardiomiociti, che derivano da un progenitore 
CD34+. Dati recenti ottenuti da modelli sperimentali di diabete tipo 1 e tipo 2 
indicano l’esistenza di difetti midollari che includono microangiopatia, neuropatia, 
alterazione dell’espressione genica e disfunzione della nicchia staminale.  
Obiettivi. Questo set di esperimenti ha avuto l’obiettivo di descrivere in dettaglio 
le alterazioni della funzione midollare nel diabete clinico e sperimentale. 
Metodi. Gli approcci metodologici sono diversificati e comprendono: 1) un trial di 
stimolazione midollare diretta con G-CSF ricombinante umano in pazienti con e 
senza diabete; 2) un’analisi di meta-regressione dei trials in cui il G-CSF è stato 
somministrato per indurre rigenerazione cardiovascolare in pazienti con e senza 
diabete; 3) lo studio della compartimentalizzazione delle cellule 
staminali/progenitrici nel midollo e nel sangue periferico, in relazione al diabete; 
4) un modello animale per la definizione del ruolo di DPP-4 nel difetto di 
mobilizzazione midollare associato al diabete. 
Risultati. Parte 1: in risposta al G-CSF, le cellule CD34+ circolanti aumentavano 
significativamente nel paziente non diabetico, ma non nel diabetico, che 
mostrava anche una difettosa mobilizzazione di cellule ematopoietiche CD133+ e 
CD34+CD133+, nonché di cellule progenitrici endoteliali CD133+KDR+, 
indipendentemente dai possibili fattori confondenti. La capacità angiogenica in 
vivo delle cellule mononucleate aumentava significativamente dopo G-CSF nei 
soggetti diabetici ma non nei non diabetici, rispetto al basale. Il diabete risultava 
associato ad una incapacità di upregolare DPP-4 sulle cellule CD34+ in risposta 
al G-CSF. 
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Parte 2: per la meta-regressione sono stati individuati 227 articoli, recuperati 96 e 
trattenuti 24 per l’analisi primaria. È stata identificata una forte correlazione 
negativa tra prevalenza del diabete all’interno di ogni trial e livello delle cellule 
CD34+ raggiunte dopo mobilizzazione con G-CSF (r=-0.68; p<0.0001). Una 
analisi di regressione multipla ha confermato che il risultato era indipendente da 
possibili fattori confondenti. In 13 articoli contenenti dati sui livelli di cellule 
CD34+ pre- e post-G-CSF, la correlazione negativa tra prevalenza del diabete e 
mobilizzazione appariva ancora più stretta (r=-0.82; p<0.0001). 
Parte 3: i livelli delle cellule CD34+ nel midollo e nel sangue periferico risultano 
essere direttamente correlati e la maggior parte delle cellule CD34+ erano di 
origine midollare, non proliferanti e non apoptotiche. Lo studio della 
compartimentalizzazione delle cellule CD34+ in 72 pazienti con e senza malattia 
cardiovascolare mediante l’uso delle mappe auto-organizzanti ha permesso di 
rilevare alterazioni della mobilizzazione in presenza di diabete ed elevato rischio 
cardiovascolare. Inoltre, un’elevata attività plasmatica di DPP-4 si associava ad 
alterata compartimentalizzazione delle cellule CD34+. In ratti diabetici rispetto ai 
controlli, l’attività di DPP-4 risultava significativamente aumentata nel sangue 
periferico e ridotta nel midollo osseo. Lo studio di ratti geneticamente deficienti 
dell’enzima DPP-4 ha permesso di stabilire che l’alterazione tessuto-specifica di 
DPP-4 nel diabete è responsabile del difetto di mobilizzazione post-G-CSF e 
post-ischemia. La delezione di DPP-4 ripristinava la mobilizzazione post-
ischemica di cellule staminali ematopoietiche e progenitrici endoteliali e favoriva il 
recupero del tessuto ischemico nel diabete. 
Conclusioni. Diversi tipi di evidenze sperimentali indicano chiaramente che il 
diabete induce un difetto nella mobilizzazione delle cellule staminali/progenitrici 
midollari. Questo difetto primitivo del midollo osseo nel diabete è correlato ad una 
disregolazione tessuto-specifica dell’attività dell’enzima DPP-4. 
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INTRODUCTION 
 
Diabetes mellitus (DM) increases cardiovascular disease (CVD) and this is 
attributed, at least in part, to shortage of vascular regenerative cells derived from 
the bone marrow (BM) (1). Indeed, DM is associated with reduced levels of 
several circulating progenitor cell phenotypes (2; 3). DM prevents post-ischemic 
progenitor cell mobilization in rats, which translates into impaired vascular 
recovery after ischemia (4). Recent data from experimental models of type 1 and 
type 2 diabetes highlight BM pathologies that include microangiopathy (5), 
neuropathy (6), altered gene expression (7) and niche dysfunction (8). These 
changes may account for an impaired mobilizing capacity in DM versus controls 
animals (9). The bone marrow (BM) harbours regenerative cells involved in the 
homeostasis of the cardiovascular system, including endothelial (EPCs), smooth 
muscle and cardiomyocytes progenitors (10; 11). These progenitor cell lineages 
derive from the common immature CD34+ stem cell population within the BM 
(11). In steady-state conditions, CD34+ cells circulate at a very low frequency 
(<0.01% of white blood cells) in peripheral blood, but can be mobilized from the 
BM by different stimuli, either physiologic or pathologic (12; 13). Vascular and 
myocardial injury, through the release of chemokines and growth factors, potently 
stimulates the BM to mobilize CD34+ cells into the bloodstream, as a reparative 
attempt (13). Preclinical studies indicate that CD34+ cells and EPCs repair the 
damaged vasculature, promote angiogenesis and favour recovery of the infarcted 
myocardium (11). Bone marrow (BM) derived stem and progenitor cells 
contribute to cardiovascular homeostasis through several mechanisms, including 
differentiation into vascular phenotypes and paracrine signals (14-17). The cross-
talks between cardiovascular disease (CVD) and the BM system are manifold. 
Signals from ischemic tissues activate BM metabolism and function (18) and 
inform the BM for the need of vasculo-regenerative cells through soluble 
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mediators (e.g. VEGF and SDF-1α) produced locally (13). These cross-talks are 
disturbed in the presence of cardiovascular risk factors (12), which are 
associated with reduced and dysfunctional BM-derived circulating progenitor 
cells, a mechanism that contribute to development and progression of CVD (19-
21). On this background, several clinical trials have been conducted during the 
last 10 years using autologous stem/progenitor cells to treat cardiovascular 
disease (CVD) (22). Cellular products were obtained by either BM aspiration or 
apheresis of peripheral blood mobilized with granulocyte-colony stimulation factor 
(G-CSF). Other trials were designed to test whether simply increasing circulating 
stem cell levels with G-CSF improved patients’ outcomes (23). Data on BM 
function in human DM are scant, while there is no information on BM structure. In 
a retrospective case series of patients undergoing BM auto-transplantation, DM 
was statistically associated with poor mobilization in response to chemotherapy 
plus human recombinant G-CSF (hrG-CSF) (8). Moreover, in support of the 
existence of a BM defect in human DM, we have shown a reduction in BM 
CD34+ cells, compared with non diabetic subjects (24). The mechanism of action 
of the mobilizing factor G-CSF is complex and involves cleavage of SDF-1α 
through release of proteases, elastases and MMP9, suppression of osteoblastic 
function, and modulation of integrins (25). The mechanism whereby DM impairs 
stem cell mobilization may depend on altered local concentrations of the 
chemokine SDF-1α. Interestingly, SDF-1α is a natural substrate of the protease 
CD26/DPP-4, the activity of which is dysregulated in DM (26). The impaired stem 
cell mobilization in DM carries important implications for the care of patients in 
the hematology clinic. Furthermore, as the BM harbours a variety of regenerative 
non-hematopoietic progenitors, BM dysfunction may contribute to the onset of 
chronic diabetic complications (27). Unfortunately, exploration of BM structure 
and function in humans is limited by the intrinsic low availability of BM samples 
from non-hematologic patients. 
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PART 1 
 
Diabetes impairs stem cell and proangiogenic cell 
mobilization in humans 
 
 
 
AIM 
 
To confirm the diabetic stem cell “mobilopathy” in humans, a pharmacologic test 
of BM reserve was herein devised in as a prospective trial of BM stimulation with 
a single subcutaneous injection of hrG-CSF in DM and in non-DM individuals. 
 
RESEARCH DESIGN AND METHODS 
 
Patients and treatment. The study was approved by the local ethical committee 
and is registered in ClinicalTrials.gov (NCT01102699). This was a prospective, 
parallel group study of direct BM stimulation with hrG-CSF in DM and non DM 
subjects. The primary end-point was change in circulating CD34+ cells from 
baseline. Secondary end-points were changes in other progenitor cell 
phenotypes, proangiogenic capacity of peripheral blood mononuclear cells 
(PBMC), white blood cells and safety. The study was not designed and powered 
to detect baseline differences in progenitor cell levels. DM patients were recruited 
at the outpatient clinic of the University Hospital of Padova and healthy control 
subjects were volunteers from the local community. Both type 1 and type 2 DM 
patients were eligible because pre-clinical studies have shown similar BM 
alterations and progenitor cell reductions in both types of DM (5; 6). Exclusion 
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criteria were: age <25 or >65 years, any acute disease or infection, recent 
trauma, surgery or cardiovascular event, chronic immune or infectious diseases, 
current or past hematological disorders or malignancy, leukocytosis, leukopenia 
or thrombocytopenia, organ transplantation or immune suppression, advanced 
diabetic retinopathy, altered liver function, severe renal failure (eGFR<30 
mL/min/m2), anomalies in lymphocytes subpopulations, allergy to Filgrastim, 
bronchial asthma or other chronic lung disorders, impossibility to provide 
informed consent. For each patient, we collected anthropometric measures, data 
on concomitant risk factors, HbA1c, eventual diabetic complications and therapy.  
After providing informed consent, patients were subjected to baseline 
examination and blood samples, including determination of the complete 
leukocyte counts and lymphocyte subpopulations, liver enzymes, renal function, 
plasma protein electrophoresis, erythrocyte sedimentation rate, C-reactive 
protein, prothrombin time, uric acid and standard urine exam. After verification of 
inclusion and exclusion criteria, at h8.30 am after an overnight fast, eligible 
patients were subjected to a baseline peripheral blood sampling for circulating 
progenitor cell quantification and collection of PBMC. Immediately after, they 
were injected subcutaneously with 5 µg/kg Filgrastim (Granulokine, Amgen). 
Twenty-four hours later, another peripheral blood sample was obtained to 
evaluate the effects of Filgrastim. Study subjects were invited to register and 
report any eventual side effect occurred after Filgrastim injection. Dosage of the 
drug was chosen as the minimum effective dose based on available 
pharmacodynamic data on Filgrastim, showing that 5 µg/kg is sufficient to 
increase absolute count of circulating CD34+ cells in healthy controls (28). 
 
FACS analysis. Circulating progenitor cells were quantified using flow cytometry 
as previously described in detail (29). Briefly, after red blood cell lysis, 150 µl of 
peripheral blood were stained with 10 µl of FITC-conjugated anti-human CD34 
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mAb (Becton Dickinson), 10 µl of PE-conjugated anti-human KDR mAb (R&D 
Systems) and 10 µl of APC-conjugated anti-CD133 mAb (Miltenyi Biotech). The 
frequency of peripheral blood cells positive for the above reagents was 
determined by a 2D side scatter-fluorescence dot plot analysis, after appropriate 
gating. We gated CD34+ or CD133+ peripheral blood cells in the mononuclear cell 
fraction and then examined the resulting population for the dual expression of 
KDR. At the intersection of the CD34 and CD133 gates we identified 
CD34+CD133+ cells, which were examined for KDR expression. In all patients, 
we also quantified the expression of CD26/DPP-4 on CD34+ cells using a PE-
labelled anti-CD26 mAb (BD). In separate analyses, CD45 co-staining was 
performed and showed that >90% of CD34+ cells are CD45dim. For FACS 
analysis, 5x105 cells were acquired and scored using a FACS Calibur (BD). Data 
were processed using the Macintosh CELLQuest software program (BD). The 
same trained operators, blind to the clinical status of the patients, performed the 
tests throughout the study. Absolute progenitor cell counts per unit of blood were 
derived by multiplying fractional data per white blood cell count. We have 
previously shown that reproducibility of CD34+ cell quantification with this method 
is high (ICC 0.94, 95% C. I. 0.88-0.96; CV 6.3%) (29). 
 
In vivo proangiogenic cell function. To gather information on the presence of 
functional circulating proangiogenic cells and how they are modulated by hrG-
CSF in DM and non DM subjects, we used the in vivo Matrigel plug angiogenesis 
assay with patients’ PBMC. Indeed, data suggest that diverse monocyte subsets, 
including monocytic EPCs and Tie2-expressing monocytes, have proangiogenic 
capacity (30; 31). Briefly, PBMC were isolated with Histopaque (Sigma-Aldrich). 
Cell count and viability were assayed with an automated BioRad TC20 cell 
counter. Then, 3 x 106 PBMC were resuspended in 500 µL phenol-free Matrigel 
(BD, cat no. 356237) and implanted subcutaneously into the dorsum of 
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immunodeficient RAG-2/gamma(c) double knock-out mice (in-house colony). The 
experiment was performed with pre- and post-hrG-CSF PBMC of n=5 non DM 
controls, n=5 T1D patients and n=5 T2D patients. To minimize variability, the 
same mouse received pre- and post-GCSF PBMC of the same subject. Plugs 
were explanted 10 days later for macroscopic inspection, histology (H&E 
staining), and determination of the hemoglobin/protein content ratio (Drabkin’s 
solution and Bredford reagent respectively, Sigma-Aldrich), which is as a 
surrogate of perfusion. Hb/protein ratio was adjusted for the change in monocyte 
count after hrG-CSF to gather information on the proangiogenic capacity of 
circulating PBMC at each time point.  
 
Statistical analysis. Data are expressed as mean±standard error (SE). Normal 
distribution of the variables of interest was verified with the Kolmogorov-Smirnov 
test. Comparisons between the diabetic and non diabetic group were performed 
using Student’s t test for normal variables, Mann-Whitney’ U test for non-normal 
variables and the chi-square test for categorical variables. As CD34+ cell count is 
a normally distributed variable, the change in CD34+ cell count from baseline to 
24h after Filgrastim was assessed using paired Student’s t test. We then 
calculated the mean±SE change of CD34+ cells in the diabetic and non diabetic 
groups, which were compared using unpaired Student’s t test. Linear 
associations were assayed using the Pearson’s r correlation coefficient. To 
control for variables that were different between the 2 groups at p≤0.10 and may 
bias results, a multiple linear regression analysis was run with change in 
progenitor cell levels as the dependent variable. Non-normal dependent variables 
in secondary end-point analyses were log-transformed. Statistical significance 
was accepted at p<0.05 and SPSS version 17.0 was used. 
 
RESULTS 
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Characteristics of the study population. A total of 24 DM patients (10 T1D and 
14 T2D) and 14 non DM controls have been enrolled and treated. Diabetic 
patients had a higher prevalence of hypertension and tended to be older than 
control subjects. T1D patients had a significantly longer disease duration and 
lower prevalence of cardiovascular disease, compared to T2D (Table 1). 
  
Stem and progenitor cell mobilization. In non DM subjects, absolute CD34+ 
cell level significantly increased 2.2-fold after hrG-CSF, while DM patients 
completely failed to mobilize CD34+ cells (mean±SE change versus baseline: non 
DM 3475±800 cells/mL; DM 52±332 cells/mL; p=5x10-5; Figure 1A). Results were 
similar when T1D or T2D patients, considered separately, were compared with 
age-matched non DM controls (Figure 1B-C). Clinical characteristics of the 
subgroups are shown in Table 1. 
After adjusting for potential confounders that were different between the 2 groups 
at p≤0.10 (age, hypertension and cardiovascular disease), DM remained 
significantly associated with reduced CD34+ cell increase after hrG-CSF 
(p=0.002). 
In response to hrG-CSF, DM was associated with impaired mobilization of all the 
other progenitor cell phenotypes, such as CD133+, CD34+CD133+, CD34+KDR+, 
CD133+KDR+ and CD34+CD133+KDR+ cells (Figure 2). Upon correction for 
potential confounders, DM remained significantly associated with defective 
mobilization of CD133+ (p=0.015), CD34+CD133+ (p=0.011) and CD133+KDR+ 
(p=0.013) cells, while the association between defective CD34+KDR+ mobilization 
and diabetes was marginally significant (p=0.056) and blunted by age (p=0.024). 
Percentage expression of CD26/DPP-4 on CD34+ cells significantly increased 
after hrG-CSF in non DM controls (delta +14.1±3.9%), consistent with previous 
findings in vitro (32). In DM, CD26/DPP-4 expression was elevated at baseline 
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and tended to decline after hrG-CSF treatment (delta -8.8±5.5%, p=0.013 vs non 
DM. Figure 3). 
In the DM groups, progenitor cell mobilization was not significantly correlated to 
HbA1c, disease duration, pattern of complications or treatment regimen. 
After treatment with hrG-CSF, WBC, neutrophil and monocyte counts significantly 
increased in both groups and there were no differences between DM patients 
and non DM controls (Table 2 and Figure 5). This suggests that DM affects 
immature and not mature cell mobilization. 
 
Proangiogenic cell function in vivo. Patients’ mononuclear cells collected 
before and after hr-GSCF administration were embedded into Matrigel plugs and 
implanted in immunodeficient mice to assess the presence of proangiogenic 
cells. Baseline PBMC from non DM subjects showed higher neovascularisation 
capacity compared to DM patients, which was statistically significant versus T1D. 
Plugs with non DM PBMC before hrG-CSF (baseline) showed vascular invasion 
at gross inspection and the presence of vascular structures containing 
erythrocytes at histology. Plugs implanted with T1D PBMC at baseline showed 
almost no vascularization, lower hemoglobin content and no evidence of 
perfused vascular structures. Plugs containing baseline T2D PBMC showed non-
significantly lower vascularisation capacity compared to non DM at baseline. After 
hrG-CSF, the proangiogenic capacity of patients’ cells significantly increased in 
non DM, but not in DM groups, and post-hrG-CSF neovascularisation capacity 
was lower in T1D (p=0.058) and T2D (p=0.045) versus non DM (Figure 4). 
Matrigel plug neovascularisation capacity was significantly correlated with 
circulating CD34+ (r=0.47; p=0.003), CD34+KDR+ (r=0.38; p=0.024), 
CD133+KDR+ (r=0.46; p=0.005) and CD34+CD133+KDR+ (r=0.41; p=0.014) cell 
levels (Figure 6). These data suggest that hrG-CSF mobilizes functional 
proangiogenic cells in non DM subjects but not in DM patients. 
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Safety. Treatment with hrG-CSF was safe and uneventful: 5 subjects in the non 
DM group (35.7%) and 5 patients in the DM group (20.8%, p=0.53 DM vs. non 
DM) reported mild back pain 12 to 18 hours after Filgrastim injection, which 
resolved at 24h and required analgesic therapy with acetaminophen in 3 non DM 
cases.  
 
DATA INTERPRETATION AND DISCUSSION 
 
We show that DM is associated with impaired stem and progenitor cell 
mobilization after direct BM stimulation, independently of potential confounders. 
Remarkably, this was true for both hematopoietic stem cells and EPCs despite 
baseline cell levels were not reduced in this DM cohort. Therefore, the present 
prospective trial substantiates the existence of a BM defect in human DM and 
suggests that the BM mobilization failure precedes reduction of circulating 
progenitors. Both T1D and T2D patients showed almost complete 
unresponsiveness to stem/progenitor cell mobilization, suggesting that this 
complication is independent of DM etiology; however, the role of autoimmunity in 
determining BM response may be worth of investigation. 
In mice, long-term DM causes BM microangiopathy and altered oxygen gradients 
(5) that, in addition to reduced expression of pro-survival genes (7), lead to a 
pauperization of the stem cell pool. Microvascular BM alterations in experimental 
DM include capillary rarefaction, increased permeability, endothelial cell 
apoptosis and dysfunction (5), features that resemble diabetic microangiopathy of 
other organs, such as the kidney and retina. These histopathological aspects 
suggest that the BM is a hitherto unrecognized site of diabetic complication and 
are likely responsible for the mobilization failure. Data on the amount of BM stem 
cells in diabetes are discordant, with some studies showing normal (4; 33) or 
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even increased (8) primitive Sca-1+c-kit+Lin- hematopoietic progenitors. 
Therefore, the low CD34+ cell count in BM aspirates from type 2 DM patients that 
we have previously shown (24) might reflect true stem cell deficiency or reduced 
accessibility of the niches to aspiration, owing to the sticky property of the 
diabetic niche, which is more prone to stem cell retention than mobilization (8). 
Importantly, DM did not impair mobilization of mature leukocytes, which are more 
loosely retained by the BM stroma than stem cells. 
Normally, G-CSF stimulates expression and activity of CD26/DPP-4 and other 
proteases, with subsequent degradation of the chemokine and retention signal 
SDF-1α (32; 34). Thus, stem/progenitor cells migrate to the peripheral circulation 
following SDF-1α gradients. Herein, we suggest a possible mechanism of stem 
cell unresponsiveness to G-CSF in DM, by showing a maladaptive CD26/DPP-4 
response. Systemic CD26/DPP-4 activity is increased in DM (26), and our new 
data indicate that G-CSF fails to upregulate CD26/DPP-4 on BM-derived cells in 
DM, likely preventing modification of the SDF-1α gradient. Studies show that DM 
mice mobilize stem cells after treatment with the SDF-1α receptor CXCR4 
antagonists AMD3100 (8; 33; 35) and NIBR1816 (36). Therefore, the vascular 
niche containing stem cells that can be readily mobilized upon disruption of the 
SDF-1α retention signal seems to be preserved, but responsiveness to CXCR4 
antagonists should be confirmed in DM patients. 
The existence of a BM mobilopathy in DM might be ascribed to both structural 
alterations affecting the stem cell niche (microangiopathy) and functional defects 
preventing the cells from being mobilized (e.g. the CD26/SDF-1α/CXCR4 axis). 
Additionally, DM alters the activity of endothelial nitric oxide synthase (eNOS) 
(37) which is pivotal for EPC mobilization (38) and, though G-CSF activity is 
mainly eNOS-independent (39), this may be another mechanism accounting for 
depressed mobilization in DM. Among strategies to reverse BM dysfunction, our 
data showing no correlation between HbA1c and mobilization suggest that 
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glucose control might not be effective, while experimental data indicate that 
boosting the anti-oxidative defence is a suitable strategy to prevent BM 
alterations (5). Though CD26/DPP-4 inhibition increases EPCs (40), whether this 
represents a therapeutic target to restore BM responsiveness in DM needs to be 
ascertained. 
We also found that DM impairs neovascularisation by mononuclear cells 
mobilized by hrG-CSF, as shown by the in vivo Matrigel plug assay. Interestingly, 
T1D patients already had defective neovascularisation capacity at baseline. This 
is possibly related to the longer disease duration in T1D versus T2D patients 
(Table 1). Both T1D and T2D patients were unable to increase significantly their 
PBMC proangiogenic capacity after hr-GCSF, again suggesting that mobilization 
failure precedes reduction of proangiogenic cells. Although we did not identify the 
subpopulation of PBMC involved (30; 31), change in neovascularisation capacity 
was correlated with stem/progenitor mobilization. These important results indicate 
that the stem cell mobilization failure can be pathophysiologically linked to 
impaired tissue repair and development of cardiovascular diabetic complications, 
which are characterized by defective angiogenesis (41; 42).  
These findings have clinical implications. Reduced progenitor cell levels are 
powerful predictors of future cardiovascular events (21), and replenishment of 
progenitor cells may lower cardiovascular risk. Although the pathogenesis of 
diabetic vascular complications is complex and possibly diversified in T1D and 
T2D, it is remarkable that alterations in BM-derived cells have been consistently 
reported for both T1D (43) and T2D patients (44). Understanding the causes of 
progenitor cell reduction and the role of BM can identify novel strategies to 
reverse this defect and prevent vascular disease. Moreover, the 
immunomodulatory activity of mobilized BM-derived progenitors may be 
important in T1D (36). In addition, clinicians should be aware of the likelihood of 
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mobilization failure in DM patients undergoing stem cell collection for BM 
autotransplantation or for angiogenic cell therapy (8; 9).  
The study has limitations. First, replication in other, possibly larger, cohorts is 
needed and comparison between recent-onset and long-term T1D patients would 
allow a description of the natural history of BM dysfunction. Second, while the 
imbalances in clinical characteristics between groups were adjusted by 
multivariate analyses, residual confounding may be present. Finally, while a 
single-dose hrG-CSF was used in this study, DM patients might respond to a full 
5-day course of hrG-CSF, but it would not be ethical to perform maximal BM 
stimulation for research purposes only. Several DM patients have been treated 
with high-dose hrG-CSF in cell therapy protocols (45), but a formal comparison of 
the mobilization effect between DM and non DM patients has never been 
performed. Nonetheless, our data represent a proof-of-concept of diabetic BM 
dysfunction in humans. As the BM emerges as a novel target organ in DM, 
intensive investigation to reverse this complication becomes compelling. 
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PART 2 
 
Diabetes impairs mobilization of stem cells for the 
treatment of cardiovascular disease.  
A meta-regression analysis 
 
 
 
AIM 
 
In Part 1, we have shown that response to low dose hrG-CSF is impaired in 
diabetic compared to non diabetic subjects involved in a trial of direct BM 
stimulation to assess BM reserve. In this substudy, to test whether this holds true 
also in a setting that is more relevant to diabetic complications, data on trials of 
G-CSF administration in patients with CVD were collected. Given that studies do 
not normally report mobilization efficiency in DM versus non DM patients, a meta-
regression analysis testing the correlation between CD34+ cell levels and 
prevalence of DM in the study cohort was performed. 
 
MATERIALS AND METHODS 
 
Objective. The study was conducted to detect a significant correlation between 
prevalence of diabetes in each trial and achieved absolute CD34+ cell count 
(cells/µL) after G-CSF stimulation, as an indicator of mobilization (primary end-
point). A separate analysis was pre-specified for trials reporting CD34+ cell levels 
before and after G-CSF administration. Finally, we looked for studies eventually 
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reporting CD34+ cell levels separately for DM and non DM patients or individual 
patients data.  
 
Literature search. We searched the English literature from 1997 to 2012 (last 
updated 30 Aug 2012) for articles describing clinical trials in which patients with 
CVD were subjected to G-CSF stimulation for BM CD34+ stem cell mobilization 
alone or followed by apheresis and cell therapy. The search terms were: ("trial" 
OR "patients" OR "patient") AND ("G-CSF" OR "GCSF" OR "granulocyte colony") 
AND ("CD34" OR "HSC" OR "stem cell" OR "stem cells") AND ("mobilization" OR 
"mobilized" OR "mobilize") AND ("vascular" OR "cardiovascular" OR "myocardial" 
OR "cardiac" OR "critical" OR "arterial" OR "coronary artery disease" OR 
"angina" OR "heart failure"). We also examined cross-references among different 
articles. The minimal criteria for inclusion of the study in the primary analysis 
were: 1) description of the study cohort with clear indication of the prevalence of 
diabetes; 2) clear reporting of G-CSF dosage and treatment duration; 3) 
indication of the absolute CD34+ cell count (in cells/µL of peripheral blood) 
achieved after the course of G-CSF administration. 
 
Quality assessment. Quality of the trials included in this meta-analysis was 
assessed according to an itemized methodological quality graph, as suggested 
by the Cochrane Handbook for Systematic Reviews of Interventions (46). Each 
item was scored as low, uncertain, or high risk of bias. The items included in the 
checklist and visualized in the graph were selected based on their relevance to 
the meta-regression on CD34+ cell mobilization. Therefore, detection bias was 
not related to the primary outcome of the trial, but on integrity of CD34+ cell data. 
Attrition bias was not considered, as availability of CD34+ cell data was an 
inclusion criterion. Quality was scored by the 2 authors independently. Quality 
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assessment was meant to generate separate analyses limited to trials with low 
risk of bias.  
 
Data retrieval. We collected the following data: mean ± SD age of the patients, 
percentage of male patients, prevalence of diabetes, hypertension, dyslipidemia, 
and smoking habit, underlying disease, baseline CD34+ cell count/µL (when 
available), achieved CD34+ cell count/µL after the course of G-CSF stimulation. 
Total dose of G-CSF (µg/kg) received  by the patient was calculated as daily 
dose (µg/kg/day) multiplied by the duration of treatment in days. The standard 
course of G-CSF stimulation is 5 µg/kg b.i.d. for 5 days, for a total of 50 µg/kg. As 
the total dosage varied considerably among studies, in order to make the 
achieved CD34+ cell count comparable, we normalized CD34+ cells/µL to the 
standard 50 µg/kg dosage using a proportionality formula: adjusted CD34+ 
cells/µL = reported CD34+ cells/µL × 50 ÷ total µg/kg G-CSF administered. In 
case the CD34+ cell count/µL was not directly reported, this was calculated by 
multiplying % of CD34+ cells in peripheral blood for total white blood cell 
count/µL. When CD34+ cell count was reported only in figures and not in the text, 
data were extrapolated from figures, but these data were considered low quality 
and marked as such. 
 
Statistical analysis. Data are expressed as mean ± SD or as percentages, 
where appropriate. For merging continuous normal data from different studies 
(e.g. age) in order to provide a global overview of patients characteristics, we 
calculated the weighted average and standard deviation. Heterogeneity among 
studies was calculated using the chi-square test. The correlations between 
prevalence of diabetes and achieved CD34+ cell count or increase in CD34+ cell 
count were checked using the meta-regression method described by Thomson 
and Higgins (47), with the random effect model. Pearson’s r and Spearman’s rho 
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correlation coefficients were also calculated. A multivariate analysis was run to 
verify whether the correlation between prevalence of diabetes and CD34+ cell 
count was independent from the prevalence of other risk factors and underlying 
disease. The PRISMA guidelines were used to compile and report the data (48). 
Statistical significant was accepted at p<0.05. 
 
RESULTS 
 
Search results. Based on search criteria, we initially retrieved 227 articles for 
screening. Of these, 96 were retained for further evaluation, while the others 
were discarded as non relevant. Twenty-four articles were finally included in the 
analysis of the primary end-point, with two trials reporting two groups with 
different G-CSF dosages, which were considered separately (Table 3). Of the 24 
articles, 13 also reported the baseline CD34+ cell count, which allowed a 
calculation of the increase in CD34+ cells after G-CSF stimulation (Figure 7). In 
one trial only, crude data of individual patients were reported (49), allowing a 
calculation of the achieved CD34+ cell count in DM and non DM patients.  
 
Data quality assessment. Data quality is represented by an itemized 
methodological quality graph (Figure 8). Most studies (70%) were randomized, 
controlled trials almost free from baseline imbalance, in which patients were 
randomly assigned to treatment with G-CSF or placebo. This suggests that the 
risk of selection bias was low. Quality of CD34+ cell data was high in 80% of 
cases: in 2 trials data were calculated from % of CD34+ cells and WBC counts 
(uncertain risk of bias); in 3 trials, CD34+ cell levels were derived from figures 
(high risk of bias). Blinding was relatively low, but this was unlikely to affect the 
effects of G-CSF on CD34+ cells. 
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Study population. Pooled characteristics of the study population are reported in 
table 4. On average, patients were about sixty year old, prevalently males, 
treated for ST-elevation myocardial infarction. In most trials, prevalence of DM 
was lower than that of other traditional risk factors, reflecting the typical 
characteristics of patients in cardiovascular trials. The total dose of G-CSF 
administered was close to the standard 50 µg/kg dose, over a period of about 6 
days. However, there was considerable heterogeneity in patients characteristics 
and treatment protocol among studies. Importantly, the chi-square test for 
heterogeneity among studies was statistically significant (p<0.0001), indicating 
that the study differed in the degree of CD34+ cell mobilization. 
 
Meta-regression analysis. The primary aim of the analysis was to find a 
correlation between prevalence of DM and achieved absolute CD34+ cell count 
after G-CSF administration. Simple correlation analysis revealed a strongly 
significant negative correlation (r = -0.68; p < 0.0001; rho = -0.65; p < 0.0001). 
Using the random effect model by Bayesan tau taking into account weights of the 
single trials, the negative correlation was as well highly significant (p < 0.0001; 
equation y = a + bx where a = 91.2±11.4; b = -1.4±0.3. Figure 9A). The analysis 
of variance (calculated as the residual error sums of squares and estimated using 
the chi squared test) was not significant (p=0.72), indicating no residual 
heterogeneity among trials. Excluding trials in which the absolute CD34+ cell 
count / µL was calculated or derived from figures (n=5), the correlation did not 
change (r = -0.69; p < 0.0001; rho = -0.62; p < 0.0001). Similarly, limiting the 
meta-regression to randomized, controlled trials did not modify strength of the 
association (r = -0.69; p < 0.0001; rho = -0.61; p = 0.008). These results indicate 
that data quality did not affect the correlation between prevalence of DM and 
achieved CD34+ cell count. 
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Including in the meta-regression only trials of patients with heart disease, thus 
making the population more homogeneous, did not significantly modify the 
correlation (r = -0.62; p = 0.002; rho = 0.56; p = 0.005). Further limiting to trials on 
ST-elevation myocardial infarction slightly blunted the correlation strength (r = -
0.51; p = 0.034; rho = -0.48; p = 0.049). 
The secondary aim was to find a correlation between the increase in CD34+ cell 
count after G-CSF and prevalence of DM. To this end, only trials reporting pre- 
and post-G-CSF data were included. The simple correlation analysis revealed an 
even stronger negative association (r = -0.82; p < 0.0001; rho = -0.84; p < 
0.0001), which was also highly significant using the random effect model meta-
regression (p < 0.0001; equation y = a + bx where a = 63.5±8.3; b = -1.0±0.3; 
Figure 9B), again with no residual heterogeneity (p=0.91). This result indicates 
that including only trials with high quality data made the correlation even stronger. 
We then looked at correlations with prevalence of other risk factors, mean age or 
underlying disease and only found marginal direct correlations with prevalence of 
male gender (achieved CD34+ cell count: r = 0.36; p = 0.067; rho = 0.34; p = 
0.088; increase in CD34+ cell count: r = 0.48; p = 0.067; rho = 0.45; p = 0.092), 
which were not significant in the meta-regression with the random effect model 
(p=0.07 and p=0.13 respectively). 
Finally, a multivariable analysis showed that the association between prevalence 
of DM and achieved CD34+ cell count was independent of age, other risk factors, 
underlying disease, and sample size (Table 5).  
 
DATA INTERPRETATION AND DISCUSSION 
 
The present study shows that, in clinical trials in which patients with CVD were 
treated with G-CSF for stem cell mobilization, the prevalence of DM is a negative 
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determinant of the achieved CD34+ cell level. This observation suggests that DM 
impairs the mobilization response to G-CSF and has 2 possible implications.  
First, DM patients undergoing angiogenic cell therapy with mobilized peripheral 
blood stem cells are likely to receive a lower cell dose compared to non DM 
patients. In one study analyzing the outcome of 111 patients implanted with G-
CSF-mobilized peripheral blood stem cells for the treatment of critical limb 
ischemia, a low dose of CD34+ cells was associated with a significantly shorter 
amputation-free survival (50). Additionally, 2 meta-analyses of stem cell therapy 
for ischemic heart disease showed that cell dosage is a direct determinant of the 
improved outcome (51; 52). 
Second, the inability of DM patients to adequately mobilize stem cells upon direct 
BM stimulation points to the existence of a BM defect. This is supported by 
experimental animal studies showing BM microvascular rarefaction, altered 
location of stem cells in the niches, and reduced expression of pro-survival genes 
(5-7), that turn into impaired stem cell mobilization (9). This is of paramount 
importance, as BM-derived stem cells prevent cardiovascular damage and a low 
circulating CD34+ cell level independently predicts future events (21). 
Furthermore, after myocardial infarction, the levels of CD34+ stem cells mobilized 
by endogenous G-CSF secretion is a determinant of left ventricular function at 
follow-up (53; 54). Therefore, impaired stem cell mobilization in DM may 
represent a pathophysiological link among distant end-organ complications (1; 
27). 
The meta-regression approach has intrinsic limitations. Although data dredging is 
considered the principal pitfall leading to false positive results, this is not likely to 
be a matter of concern in the  present study, because the analysis was pre-
specified and a very limited number of covariates were tested. Additionally, the 
analysis of residual heterogeneity was non-significant, indicating that prevalence 
of DM was the most important determinant of mean CD34+ cell mobilization. 
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Quality of data might also be a concern. However, limiting the meta-regression 
analysis to trials with high quality data (reporting pre- and post-G-CSF CD34+ 
cell levels) strengthened the negative association between prevalence of DM and 
CD34+ cell mobilization. Limiting the analysis to randomized, controlled trials also 
did not modify the association between prevalence of DM and mobilization. 
Publication bias cannot be fully ruled out in this meta-analysis, but is unlikely to 
be a major confounder, because the meta-regression was performed against a 
process indicator (CD34+ cells), not against the mean treatment effect (outcome 
indicator). In addition, the relationship between prevalence of diabetes and 
CD34+ cell mobilization in a given trial is unlikely to affect publication. 
Importantly, our analysis should be considered as an ecological association 
extrapolated to individual patients, because the prevalence of DM is a summary 
of patient characteristics rather than a specific attribute of the trial. In other terms, 
trials in which patients had a higher prevalence of DM showed lower CD34+ cell 
mobilization, rather than patients with DM necessarily being the actual patients 
with lower CD34+ cell mobilization. Unfortunately, this issue cannot be further 
investigated without individual patient data. In the unique trial reporting individual 
patient data, CD34+ cell mobilization in non DM patients was 2.8-fold higher than 
in DM patients, supporting validity of the extrapolation of this meta-regression to 
individual patients (49).  
Finally, it should be noted that all patients included in this meta-regression 
analysis had severe CVD and the interaction between DM and CVD in affecting 
stem cell mobilization cannot at present be dissected, nor it is possible to 
generalize these findings to DM patients without CVD. 
To sum up, this meta-regression study supports the existence of a mobilization 
failure in DM patients receiving G-CSF for the treatment of CVD. As mounting 
evidence indicate that DM affects the BM microenvironment and stem cells 
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involved in vascular repair, intensive investigation into this hitherto unrecognized 
diabetic complication is warranted. 
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PART 3 
 
Stem cell compartmentalization in diabetes and high 
cardiovascular risk reveals the role of DPP-4  
in diabetic stem cell mobilopathy 
 
 
 
AIM 
 
In this substudy, we aimed to gather information on the clinical phenotype 
associated with an altered compartmentalization of stem/progenitor cells in the 
BM and peripheral blood (PB), which would be indicative of the mobilization 
capacity. Starting from these phenotypes, we devised a clinical data-driven 
approach to test the association of candidate regulators of angiogenesis with 
progenitor cell mobilization, to be validated in animal models. 
 
MATERIALS AND METHODS 
 
Patients. All studies involving human subjects were approved by the local ethical 
committee and conducted in accordance to the Declaration of Helsinki as revised 
in 2000. Patients with heart disease and healthy controls were recruited at the 
Johann Wolfgang Goethe University Hospitals. Patients with ischemic or non-
ischemic heart disease were enrolled in protocols of progenitor cell therapy, 
which also included quantification and functional evaluation of progenitor cells in 
the BM aspirates and PB. The ethics review board of Goethe University 
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(Frankfurt, Germany), approved the protocols, and the studies were registered on 
Clinicaltrials.gov (NCT00962364 and NCT00284713). All patients undergoing BM 
aspiration for myocardial cell therapy in the trials NCT00962364 and 
NCT00284713 were eligible pending they did not have acute myocardial 
infarction. After giving informed consent, before undergoing cell therapy, patients 
were subjected to BM aspiration under sedation or general anesthesia. A small 
volume (about 1 mL) of the BM aspirate was collected for progenitor cell 
quantification. At the same time, a PB sample was drawn from a peripheral vein. 
Young healthy volunteers from the staff or the local community were subjected to 
the same procedure after providing informed consent for BM aspiration and 
collection of a venous PB sample. 
For all subjects, we collected the following data: age, sex, prevalence of 
cardiovascular risk factors, total cholesterol, HDL cholesterol and triglycerides 
concentrations, fasting plasma glucose and medications. LDL cholesterol was 
calculated with the Friedwald formula. Patients were deemed to have diabetes 
mellitus if they were previously diagnosed with diabetes and/or were taking anti-
diabetic medications, or if they had a fasting plasma glucose ≥126 mg/dL (7.0 
mmol/L) on two different occasions, or a random plasma glucose ≥200 mg/dL 
(11.1 mmol/L) associated with symptoms of hyperglycemia, or if they had a 
HbA1c ≥6.5%, measured by HPLC. None of the patients were taking medications 
active on the incretin system. Obesity was defined as a body mass index (weight 
in kilograms divided by height in meters2) ≥30 kg/m2. Patients were deemed as 
smokers if they habitually smoked one or more cigarettes per day. Hypertension 
was defined in the presence of a history of hypertension for which the patients 
were taking medications, and/or in the presence of blood pressure above 140/90 
mm Hg. Family history for CVD was defined as a history of CVD in first degree 
relatives, excluding cases occurred at an advanced age. We calculated the 
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number of CV risk factors taking into account smoking habit, family history, 
diabetes, obesity, hypertension and dyslipidemia. 
 
Measurement of plasma regulators of angiogenesis. PB plasma was obtained 
by centrifugation of venous blood samples. The plasma concentration of a panel 
of angiogenesis-regulating mediators was determined using multiplex suspension 
arrays (Bio-plex, Biorad), that permit the simultaneous automated analysis of 
several different biomolecules in a single microplate well. We used the 
angiogenesis array, which is designed to measure at the same time the following 
analytes: Angiopoietin-2, Follistatin, G-CSF, HGF, IL-8, Leptin, PDGF-BB, 
PECAM and VEGF. In parallel, we also used a custom multiplex array for the 
simultaneous automatic measure of IL18, SCF and SDF-1α. 
 
Determination of DPP-4 activity. To measure plasma DPP-4 activity, we used 
the DPP-4 drug discovery Kit (Enzo Life Sciences, Farmingdale, NY, USA) with 
the Gly-Pro-para-nitroaniline (pNA) chromogenic substrate, according to the 
manufacturer's instructions. We have previously shown that this assay is able to 
detect significant differences in DPP-4 activity in diabetic versus non diabetic 
patients, and that the non-specific activity due to other DPP is less than 10% 
(55). Coefficient of variation of plasma DPP-4 activity, measured in replicate 
samples collected from the same patient 24 h apart, was <2%, indicating a high 
degree of reproducibility. 
 
Flow cytometry. Human progenitor cells. The level of circulating progenitor cell 
phenotype in humans was determined by a protocol standardized at our 
laboratory, using multi-color flow cytometry. Briefly, after red blood cell lysis, 
blood cells were stained with FITC conjugated anti-human CD34 (BD 
Biosciences), APC-conjugated anti-human CD133 (Miltenyi Biotec) and PE-
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conjugated anti-human KDR (VEGFR2, R&D Systems) monoclonal antibodies. 
After washing cells were analyzed using a FACS Calibur instrument (BD 
Biosciences) and the following gating strategy. In the SSC versus FSC 
morphological plot, we gated mononuclear cells and then examined this 
population for the expression of the relevant surface antigens. We first identified 
CD34+ cells, which were examined for the dual expression of CD133 and KDR. 
In the CD34+CD133+ cell gate, we also analyzed the expression of KDR to 
quantify triple positive cells. A total of 500.000 to 1.000.000 events were acquired 
for each analysis and the level of progenitor cells was expressed as number of 
positive events per 1.000.000 total events. In separate analyses, we stained 
CD34+ and CD133+ cells with a PE-conjugated anti-CD45 mAb to show that 
most (>90%) of CD34+ and CD133+ cells fall within the CD45dim region. A 
unique definition of EPCs is lacking (12); for this study, we defined CD34+, 
CD133+ and CD34+CD133+ cells as generic circulating progenitor cells (CPCs) 
and CD34+KDR+, CD133+KDR+ and CD34+CD133+KDR+ cells as EPCs. 
Cell cycle analysis. To determine the proliferation rate of circulating human 
CD34+ cells, we performed a cell cycle analysis from fresh whole blood cells for 
anonymous healthy blood donors. Briefly, after red blood cell lysis, cells were 
stained with a FITC-conjugated anti-CD34 (BD Biosciences) mAb, fixed and 
permeabilized and stained with propidium iodide (PI). DNA staining, represented 
by PI content, was examined in the morphological gate of mononuclear cells and 
in the immunological gate of mononuclear CD34+ cells. The peak of 2n diploid 
(G0/G1) cells was identified in the large population of resting circulating 
mononuclear cells. A gate of PI intensity corresponding to the G2/M phase was 
also considered. We calculated the percentages of G2-M cells (proliferation rate) 
in all mononuclear cells and in gated CD34+ cells. 
Analysis of apoptosis. The apoptotic rate of circulating CD34+ cells was analyzed 
in blood samples from healthy blood donors. Briefly, after red blood cell lysis, 
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cells were stained with a PE-conjugated anti-human CD34 mAb (BD 
Biosciences), and a FITC-conjugated Annexin V antibody (BD Biosciences), 
which recognizes early apoptotic cells that externalize phosphatidilserine. CD34+ 
cell apoptosis was assessed as the percentage expression of Annexin V on 
CD34+ cells. Dead cells were excluded from the analysis by PI staining. 
Rat progenitor cells. A unique definition of rat CPCs and EPCs is lacking. 
According to previous studies (4; 56), we defined CPCs as Sca-1+c-Kit+ cells 
and EPCs as Sca-1+CD31+ cells. Similarly to human CPC and EPC phenotypes, 
CPCs are mainly hematopoietic stem/progenitor cells, while EPCs should be 
considered to be committed toward the endothelial lineage, because of the 
expression of the endothelial marker. Briefly, after red blood cell lysis, cells were 
stained with PE-conjugated anti-Sca-1 (Cederlane) and FITC-conjugated anti-c-
Kit (CD117, BD Biosciences) or FITC conjugated anti-CD31 (BD Bisociences). 
After washing, cells were acquired and scored with a FACS Calibur instrument 
(BD Biosciences). In the SSC versus FSC morphological plot, we gated 
mononuclear cells and then examined this population for the expression of Sca-1 
and c-kit or Sca-1 and CD31, relative to the respective negative controls. A total 
of 500.000 to 1.000.000 events were acquired for each analysis and the level of 
progenitor cells was expressed as number of positive events per 1.000.000 total 
events. 
 
Fluorescence in situ hybridization. Peripheral blood samples were obtained 
form 3 women who received a bone marrow transplantation from a male donor 
more than 12 months earlier. We chose this criterion to assure complete 
hematopoietic reconstitution. This approach allowed to determine the donor or 
recipient origin of circulating CD34+ cells by analyzing that Y-chromosome 
signal. For this purpose, CD34+ cells were freshly sorted and spotted onto glass 
slides. A human Y chromosome-painting FITC-conjugate probe (Star*FISH, 
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Cambio, Cambridge, UK) was used. Slides were fixed in formaldehyde in PBS for 
5 minutes and pass through three brief rinses in 50, 70 and 100 ethanol grading, 
after washes in 2X SSC. The DNA probe was applied to the sample and co-
denatured at 85°C and then hybridized at 37°C.  Washes were performed at 
42°C in a solution of 2X SSC/0.3% Nonidet-P40 for 2 minutes. Nuclei were 
counterstained with TO-PRO 3. Probe was visualized by confocal microscope 
(TCS-SL Leica, Germany). In the positive and negative controls (represented by 
male and female cytospin from normal pheripheral blood), at least 200 nuclei 
were counted to test the efficiency of the probes. Efficiency of hybridization was 
89%. The chimerism index was assessed by dividing the number of Y-
chromosome-positive cells by the total number of cells of interest. 
Microphotographs were taken with a TCS-SL laser scanner confocal microscope. 
 
Animal experiments. The animal protocol was approved by the Local and 
national institutional review boards. All experiments were conducted according to 
the “Principles of laboratory animal care” (NIH publication no. 85–23, revised 
1985;  http://grants1.nih.gov/grants/olaw/references/phspol.htm). We used 8 
week old Fisher 344 (F344) wild type (WT, Charles River Laboratories) and DPP-
4 deficient (DPP4null or F344/duCrlCrlj, Charles River Laboratories, Japan) rats, 
weighting 200-250 g. F344/duCrlCrlj rats express Dpp4 mRNA but lack DPP-4 
activity because of the translation of abnormal isoforms that fail to be processed 
to the biologically active mature glycosylated enzyme. We have previously shown 
that F344/duCrlCrlj rats >90% reduction in measured plasma DPP-4 activity 
compared to wild type F344 rats (1.0±0.1 U/l vs. 14.9±1.1 U/l, p<0.001) (55). 
F344/duCrlCrlj DPP4null rats have a normal phenotype compared to wild type 
F344 rats. 
Induction of diabetes. Diabetes mellitus was induced in F344 WT and DPP4null 
rats by intraperitoneal injection of streptozotocin (STZ) 20 mg/kg/day in pH 4.5 
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citrate buffer. Capillary glucose was monitored after 3, 7, 14, and 28 days using a 
point-of-care glucometer (Freestyle, Abbott Diagnostics). Control (non diabetic) 
rats were injected with an equal volume of citrate buffer. Only animals with stably 
elevated (>250 mg/dL, >13.9 mmol/L) capillary glucose were considered as 
diabetic. We also determined the level of glycated haemoglobin (HbA1c) using a 
monoclonal antibody-based method (A1c now, Bayer). Animals were housed in 
controlled conditions to avoid complications attributable to polyuria and de-
hydration that may derived from sustained hyperglycemia. Experiments were 
performed 5-7 weeks after induction of diabetes. Weigh, non fasting plasma 
glucose and HbA1c of the 4 groups of animals are reported in table 10. 
Hind limb ischemia. Hind limb ischemia was induced in F344 WT and DPP4null 
diabetic and non diabetic rats (n≥5 per group) by femoral artery and vein 
excision. Briefly, under general gaseous isofluorane anesthesia (Forane, Abbott), 
a cranio-caudal 2-cm skin incision was made at the level of the right inguinal 
ligament. After removal of excess fat and accessing the vessels and nerve, the 
nerve was gently dissected from the vessels and preserved. Then, the femoral 
artery and vein were dissected from the surrounding tissues and fascia until the 
knee, cauterized with care to spare all non vascular structures and excised. All 
visible collaterals were also cauterized and excised. The skin was then closed 
with a silk suture and animals were allowed to recover from anesthesia and 
analgesic therapy was administered. Blood samples for enumeration of rat 
progenitor cells were obtained immediately before induction of ischemia and at 
days 3 and 7 after ischemia. At day 7, rats were euthanized by intracardiac 
injection of a cocktail of embutramide, mebenzonium iodide, tetracaine (Tanax, 
Intervet Italy Srl) and the solues muscles were collected from both ischemic and 
non ischemic hind limbs for histologic analysis. Before sacrifice, mice were 
injected systemically with pimonidazole (HydroxyProbe), which forms adducts at 
thiol groups in proteins at oxygen tension < 10 mm Hg, to stain hypoxic areas. 
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G-CSF stimulation. For direct bone marrow mobilization of progenitor cells in 
F344 WT and DPP4null diabetic and non diabetic rats (n≥3 per group), we used 
human recombinant G-CSF (hrG-CSF, Filgrastim, Amgen) at the dose of 60 
microg/kg/day subcutaneously for 4 consecutive days. Blood samples were 
collected at baseline and after the last dose of G-CSF for progenitor cell count. 
 
Histology. Seven-micrometer thick cryosections of ischemic and non-ischemic 
soleus muscles from F344 WT and DPP4null diabetic and non diabetic rats were 
stained with fluoresceing-labelled BSI-Lectin (Molecular Probes) to visualize the 
vascular network. Muscle fibers were visualized using phase contrast microscopy 
and images were overlapped with fluorescence microscopy detection of Lectin. 
We quantified the number of capillaries per area of section to derive a measure of 
capillary density in 10 randomly selected microscopic fields in 10 sections per 
muscle. The ischemic/non ischemic ratio of capillary density was then computed 
for each animal.  
To visualize hypoxic areas, muscle sections were stained with a primary 
monoclonal IgG1 antibody reagent (Hydroxyprobe) that recognizes pimonidazole 
adducts in hypoxic cells. Immunohistochemical stained area were quantified 
using ImageJ in randomly selected field. 
Apoptosis was assessed in 7 µm-thick criosections using the Apoptag Red Plus 
In situ Apoptosis Detection Kit (Millipore) according to the manufacture's 
instruction. Nuclei were counterstained in blue with Hoechst 33258 (Sigma-
Aldrich, Schnelldorf, Germany) and the basement membrane was stained with a 
anti-laminin antibody (Sigma-Aldrich) and a FITC conjugated secondary antibody.  
 
Statistical analysis. Data are expressed as mean ± standard error, or as 
percentage, where appropriate. Normal distribution of study variables was 
checked using the Kolmogorov-Smirnov test. Comparison between 2 or more 
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groups was performed using Student’s t test or ANOVA (for normal variables) 
and with Mann-Whitney’s U test and Kruskall-Wallis test (for non-normal 
variables), respectively. Linear correlations were analyzed using the Pearson’s r 
(for normal variables) or the Spearman’s rho (for non-normal data) correlation 
coefficients. 
Groups of patients were created according to their progenitor cell levels as below 
(termed “low”) or above (termed “high”) the median value in the peripheral blood 
and in the bone marrow. To render the separation of patients’ groups more 
extreme, the 50° percentile cutoff was substituted with the 60° percentile cutoff as 
lower limit of the “high” groups and with the 40° percentile as the higher limit of 
the “low” groups. The resulting 4 groups were compared using ANOVA or 
Kruskall-Wallis test and then with appropriate test comparing couples of groups. 
The distribution of clinical characteristics in the 4 groups was also analyzed using 
Self-Organizing-Maps (SOM) and statistically verified visualizations in the whole 
cohort and in patients belonging to the above mentioned groups defined by the 
median values or by  the 40°/60° percentile. The SOM is an unsupervised pattern 
recognition method used for automated comparisons in a multivariate profile of 
clinical characteristics (57). In the map layout, patients with similar clinical 
characteristics are as close to each other, whereas those who have different 
characteristics are placed far apart on the map. After computing patients’ 
positions, the map is colored according to the patients’ characteristics. To obtain 
a p-value for each characteristic, a statistical test compares such color 
distribution with 10,000 random colorings obtained by permuting the data values. 
A multivariable analysis can also be performed by analyzing combined SOM 
layouts for different characteristics and was used to test the association of 
diabetes with progenitor cell compartmentalization group independently of other 
clinical features. The SOM analysis was performed with the online MeliKerion 
software and its web-based interface 
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(http://www.computationalmedicine.fi/software). Statistical significance was 
accepted at p<0.05 and SPSS ver. 16.0 was used. 
 
RESULTS 
 
Direct correlations between peripheral blood and bone marrow 
stem/progenitor cell levels. We quantified the levels of 6 stem/progenitor cell 
phenotypes in the PB and BM of 72 subjects, including 12 healthy controls and 
60 patients with heart disease (Table 6). For each cell phenotype, there was a 
significant direct linear correlation between PB and BM levels, which was 
stronger for CD34+ cells (r=0.43, Figure 10A), CD133+CD34+ cells (r=0.44) and 
CD133+KDR+ cells (r=0.50) (Table 7). These direct correlations suggest that PB 
stem cell levels are informative of the BM status. The coefficient of variation was 
lower for both PB and BM CD34+ cells, the distribution of which was normal and 
less affected by extreme data. Therefore, we focused on CD34+ cells for further 
analyses. 
 
Most circulating CD34+ cells are viable, non-proliferating and originated 
from the bone marrow. As also circulating mature endothelial cells may express 
CD34 (58), we analyzed the origin of CD34+ cells isolated from 3 female patients 
who received a male BM transplantation years before, by detecting the Y-
chromosome signal using FISH. After adjusting for hybridization efficiency (89%) 
(59), we found that 92.5±3.1% CD34+ cells were Y+, indicative of a donor BM 
origin (Figure 10B). Therefore, the contamination by non BM-derived cells within 
the population of circulating CD34+ cells is <10%. In samples of healthy blood 
donors, we also show that the apoptotic rate of circulating CD34+ cells is on 
average 4.0±0.6% and most are resting (>95% in G0-G1 phase) (Figure 10C-D). 
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Therefore, variations in the number of PB CD34+ cells are mostly attributable to 
mobilization of BM CD34+ cells. 
 
Distribution of PB and BM CD34+ cells. Despite the significant direct 
correlation between PB and BM CD34+ cell levels, data were largely dispersed 
around the regression line, suggesting that circulating CD34+ cell levels are 
associated with different mobilizing capacity. Thus, we divided patients according 
to their median values of PB and BM CD34+ cell levels. We defined as “healthy”, 
patients with high PB and high BM CD34+ cells, because most healthy subjects 
fell into this subgroup (8/12 of healthy subject, 67%). By converse, patients with 
low PB and low BM CD34+ cells were defined as “exhausted”. Patients with high 
PB and low BM CD34+ cell count were defined as “good mobilizers”, while 
patients with low PB and high BM CD34+ cells were defined as “poor mobilizers”. 
When we analyzed the clinical characteristics of these 4 groups, using 
conventional statistics, several cardiovascular risk factors were different, but a 
few reached significance (not shown). Therefore, as cases with values close to 
the medians of PB and BM cell counts were poorly informative, we excluded 
those falling within ±1 decile of the median value, to render groups more 
“extreme”. In other words, the median was substituted with the 40° and 60° 
percentiles as lower and higher cut-off, respectively (Figure11). The 40°/60° rule 
was a compromise to exclude borderline values without excess reduction of 
sample size. 
 
Stem cell compartmentalization and the cardiovascular risk profile. The 4 
groups identified by the 40°/60° percentile of PB and BM CD34+ cell counts were 
first analyzed for demographics, cardiovascular risk factors and therapies using 
conventional statistics. We found that subjects in the “healthy” group were (not 
significantly) younger, had a low number of cardiovascular risk factors (p=0.02), 
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and a low prevalence of diabetes, obesity and hypertension compared with 
patients in the “exhausted” group (post-ANOVA tests). The other groups, in which 
the compartmentalization of CD34+ cells was altered, were associated with 
higher prevalence of cardiovascular risk factors, and the “exhausted” group 
showed the worst risk profile. Among therapies, use of beta-blockers and insulin 
were higher in the group of “good mobilizers”, consistent with the previous 
findings that these drugs can increase circulating progenitor cell levels (4; 60) 
(Figure 11).  
As stem cell compartmentalization is a bi-dimensional variable, we used self-
organizing maps (SOM) to analyze the association between clinical 
characteristics of the patients and their belonging group in 2D planes. This visual 
and statistical approach shows co-localization of several high-risk features with 
the group of “exhausted” patients (age, diabetes, hypertension and obesity) or 
poor mobilizers (age, hypertension and obesity). Overlapping maps that 
represent groups with those that represent clinical features allows to describe the 
phenotype of a typical patient of each group. In compliance with its higher 
statistical power, SOM show significant and almost identical final results in the 
whole study cohort (Figure 12) and in patients of the 40°/60° percentile groups 
(Figure 17). A multivariable analysis run on SOM revealed that diabetes was 
associated with group distribution independently of age, obesity, hypertension 
and therapies. We also found that diabetes was a strong determinant of reduced 
PB CD34+ cells independently of BM CD34+ cells, suggesting that diabetes 
compromises CD34+ cell mobilization (Table 8). These data indicate that altered 
CD34+ cell compartmentalization is associated with diabetes and a high 
cardiovascular risk profile. 
Compartmentalization was then repeated for other progenitor cell phenotypes 
(Table 9). Altered PB versus BM CD133+ and CD34+CD133+ cell 
compartmentalization was associated with a high cardiovascular risk profile, 
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similar to what obtained with CD34+ cell compartmentalization. However, the 
discriminative capacity of CD34+ cells was higher, as there were more clinical 
features differing among groups. These data confirm that CD34+ cell 
compartmentalization offers the best correlate of cardiovascular risk. 
 
Stem cell compartmentalization and regulators of angiogenesis. We 
quantified the plasma concentrations of a panel of angiogenesis-regulating 
factors (Table 9). When patients were divided according to CD34+ cell 
compartmentalization, plasma VEGF concentrations and DPP-4 activity were 
lower in the “healthy” group, while other factors were not significantly different. 
SOM showed that high activity of the enzyme DPP-4 co-localizes with the 
“exhausted” phenotype (Figure 18).  
The “healthy” group according to CD133+ and CD34+CD133+ cell 
compartmentalization had higher concentrations of the pro-angiogenic factors 
Angiopoietin-2 and PDGF-BB. Compartmentalization of CD34+CD133+KDR+ 
cells revealed high SDF-1α concentrations in the “healthy” and “good mobilizer” 
groups, consistent with the notion that circulating SDF-1α mobilizes EPCs (61). 
These data indicate that some mobilizing factors may explain progenitor cell 
compartmentalization in this cohort of patients. We also suggest that this clinical 
data-driven approach is a suitable platform to identify new strategies of progenitor 
cell mobilization.  
We then aimed at validating one of these factors in diabetes, as a model of 
altered progenitor cell mobilization.  
 
DPP-4 deficiency restores ischemia- but not G-CSF-induced mobilization in 
diabetes. DPP-4 has been shown to cleave pro-angiogenic factors, including 
SDF-1α (62). Consistently with this finding, in the whole cohort of subjects, we 
found a negative correlation between DPP-4 activity and plasma SDF-1α 
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concentrations (r=-0.27; p=0.017). Plasma DPP-4 activity was also directly 
correlated to the BM/PB ratio of CD34+ cells (r=0.25, p=0.028), supporting the 
hypothesis that DPP-4 regulates CD34+ cell mobilization. DPP-4 activity is 
increased in diabetic patients and its inhibition restores EPC levels in type 2 
diabetes (40; 63). Taking into account that stem cell compartmentalization was 
associated with both diabetes and DPP-4 activity in our study, we hypothesized 
that DPP-4 may be a suitable target to restore progenitor cell mobilization in 
diabetes. We first analyzed DPP-4 activity in rats and found increased activity in 
PB and decreased activity in BM of diabetic compared to non diabetic rats 
(Figure 13). Then, we tested the bone marrow progenitor cell mobilization in wild 
type and DPP-4 deficient rats after either G-CSF stimulation or hind limb 
ischemia. 
A 5-day course of G-CSF administration increased circulating Sca-1+c-Kit+ cells 
in non diabetic wild type rats, while this effect was markedly blunted in 
streptozotocin diabetic animals. Additionally, DPP-4 activity in the BM increased 
in non diabetic but not in diabetic animals (Figure 13). DPP-4 deficiency 
completely abolished Sca-1+c-Kit+ and Sca-1+CD31+ progenitor cell mobilization 
in diabetic and non-diabetic animals (Figure 14). These results confirm previous 
findings in non diabetic mice that DPP-4 is required for the mobilization effect of 
G-CSF (64) and indicate that the reduced DPP-4 activity in the BM contributes to 
unresponsiveness to G-CSF in diabetes. 
In wild type non diabetic animals, hind limb ischemia induced a transient increase 
in Sca-1+c-Kit+ progenitor cells and Sca-1+CD31+ EPCs at day 3, which 
returned to baseline at day 7. This surge in progenitor cell levels after ischemia 
was completely abolished in wild type diabetic animals, which showed a 
paradoxical decrease in Sca-1+c-Kit+ and Sca-1+CD31+ cells at day 3 (Figure 
15A). In DPP-4 deficient rats, diabetes did not impair post-ischemic increase in 
Sca-1+c-Kit+ progenitor cells, which was similar to non diabetic rats. Rather, the 
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increase of Sca-1+CD31+ EPCs at day 3 in diabetic DPP-4 deficient rats was 
even higher than that of non diabetic DPP-4 deficient rats. As a counterpart of 
progenitor cell mobilization, we analyzed microvascular density, blood flow, 
degree of ischemia and apoptosis in muscles at day 7. Recovery of capillary 
density was slightly impaired in wild type diabetic versus non diabetic rats, while it 
was not in DPP4null diabetic versus non diabetic rats (Figure 15B). The degree 
of tissue ischemia, as assessed by staining with the hypoxic probe pimonidazole, 
was higher in diabetic compared to non diabetic animals and was significantly 
lower in DPP-4null rats (Figure 15C). Therefore, DPP-4 deficiency abolished the 
detrimental effects of diabetes on development of ischemia and skeletal muscle 
microvascular recovery. We found no significant differences in superficial skin 
perfusion as assessed by Laser Doppler Imaging (Figure 19), suggesting that 
differences in blood flow recovery among groups occur earlier than day 7. Finally, 
the number of apoptotic myofibers, assessed by the ApopTag kit (in situ TUNEL 
labelling), was very low in all samples (average<2/field) and there was a non-
significant trend toward reduced apoptosis in DPP-4null rats (Figure 20). Muscle 
DPP-4 activity was low (about 10% of that in PB) and unaffected by diabetes or 
ischemia (not shown), ruling out that local DPP-4 targets are responsible for the 
effects observed in DPP-4null rats.  
 
DATA INTERPRETATION AND DISCUSSION 
 
This study, by combining a clinical data-driven discovery approach with animal 
models, shows that altered mobilization of stem/progenitor cells is associated 
with a high cardiovascular risk profile and, in the setting of diabetes, is driven by 
a tissue-specific DPP-4 dysregulation. 
Investigation into the mechanisms of reduced progenitor cell levels has led to 
several hypothesis, including excess apoptosis and senescence. In type 2 
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diabetes, we have previously shown that apoptosis is not responsible for the 
observed low level of circulating CD34+ cells (24). Rather, animal models 
suggest that BM alterations account for depressed circulating progenitor cells in 
diabetes (5; 6; 8). Unfortunately, the poor availability of BM samples limits our 
understanding of BM function in human diabetes. Herein, we analyzed BM and 
PB samples from patients undergoing cell therapy for heart disease and healthy 
volunteers. The direct correlation between BM and PB progenitor cell levels, 
although scattered, indicates that circulating progenitor cell levels are informative 
of the BM status. We also show that most circulating CD34+ cells are BM-
derived, non-apoptotic and non-proliferating. As long as homing to the target 
tissues is not increased (65), these data indicate that variations in circulating 
CD34+ cells among patients are attributable to different capacity of BM 
mobilization. This allowed to categorize patients according to their BM and PB 
progenitor cell status into distinct mobilizer phenotypes. This original approach, 
although based on a snapshot of a dynamic system, led to the discovery that 
individuals with an altered distribution of CD34+ cells in the BM and PB display a 
strikingly high cardiovascular risk profile, characterized by aging, diabetes, 
obesity and hypertension. Using self-organizing maps, we visually and 
statistically analyzed cardiovascular risk factors in relation to the mobilizer 
phenotype: DM was strongly associated with exhaustion of PB and BM CD34+ 
cells independently of the distribution of other risk factors. While reduction of 
circulating progenitors is a consistent finding in animal and human DM, the effect 
of DM on the amount of BM progenitors is debated. Long-term diabetic mice 
appear to have reduced BM Sca-1+c-kit+ hematopoietic stem cells (5; 7), while 
short-term diabetic rats showed no reduction of BM Sca-1+c-kit+ (4) and short-
term diabetic mice had normal (33) or even increased BM Sca-1+c-kit+ (8). While 
methodological issues can explain these discrepancies, we suggest that the low 
CD34+ cell count in BM aspirates of DM patients indicates a reduced 
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accessibility of stem cell niches to the aspiration manoeuvre, in compliance with 
the observation that the diabetic BM niche is sticky and more prone to stem cell 
retention than mobilization (8). 
Among other clinical features, it appears that use of beta-blockers and insulin 
was associated with a good mobilizer phenotype. Experimental studies support a 
role for beta-blockers (60) and insulin therapy (4; 66) in improving progenitor cell 
mobilization, further indicating that the clinical phenotype associated with stem 
cell compartmentalization is biologically plausible.  
Thanks to their instructing spatial networks, SOM provide complementary and 
incremental information over classic statistical group comparison, also indicating 
that the “good mobilizer” and, to a lesser extent, the “poor mobilizer” are less well 
defined phenotypes than the “healthy” and “exhausted”, as evidence from the 
uneven spatial distribution and a high p-value. Importantly, SOM allowed 
description of relevant clinical associations in the whole study cohort and is 
independent of  the method of patients’ partitioning (the 40°/60° percentile rule).   
We tested the plasma concentration of a selected range of regulators of 
angiogenesis to evaluate whether our stem cell compartmentalization analysis is 
a suitable benchmark for the discovery of stem cell mobilizing factors. Plausible 
associations were indeed found, such as between the CD34+CD133+KDR+ 
EPCs “healthy” and “good mobilizer” phenotypes and high concentrations of the 
mobilizing chemokine SDF-1α. An in-depth analysis of the plasma proteome 
could allow the identification of new mobilizing factors. 
In addition, we found low activity of DPP-4 in the CD34+ “healthy” phenotype and 
high activity in patients with disturbed stem cell compartmentalization and 
mobilization. As peripheral DPP-4 activity is increased in DM (55), we performed 
pre-clinical experiments to validate causality of this association in the defective 
stem cell mobilization observed in DM. We employed 2 assays of stem/progenitor 
cell mobilization because the molecular mechanisms involved are different and 
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may be differently affected by DPP-4. First, we confirm that both stimuli fail to 
mobilize hematopoietic (Sca-1+c-Kit+) and endothelial (Sca-1+CD31+) progenitor 
cells in diabetic rats, lending further support to the diabetic bone marrow failure. 
There are important implications of these findings, as BM stem/progenitor cell 
mobilization after ischemia is a physiologic response, while responsiveness to 
pharmacologic stimulation could be used therapeutically (67). The phenotypes 
used to define rat and human progenitor cells differ because there is no rat 
homology of human CD34 and CD133. Moreover, Sca-1+c-Kit+ cells contain 
hematopoietic progenitor cells in mice and rats, while co-expression of the 
endothelial antigen CD31 on Sca-1+ cells is compatible with a EPC phenotype 
(12). Additionally, previous studies have found that these rat progenitor cell 
phenotypes are responsive to mobilizing stimuli (4; 56). Interestingly, DPP-4 
deficiency restored ischemia-induced progenitor cell mobilization in diabetic rats, 
reduced the degree of ischemia and preserved from the detrimental effects of 
diabetes on microvascular recovery. These data suggest that DPP-4 deficiency 
improves the outcome of ischemic tissues, although the number of capillaries in 
genetically deficient mice might be influenced by the resulting phenotype and the 
link with progenitor cell mobilization is indirect. 
We have previously demonstrated that impaired post-ischemic progenitor cell 
mobilization in diabetic rats is attributable to an altered activation of the hypoxia-
sensing system HIF-1α leading to a blunted release of the chemokine SDF-1α, a 
circulating mobilizing stimulus (4). As SDF-1α is a natural substrate of DPP-4 and 
is increased in diabetic patients after treatment with a DPP-4 inhibitor (40), 
excess DPP-4 activity is therefore one mechanism for reduced of SDF-1α in 
diabetes. Thus, we hypothesize that restored peripheral SDF-1α concentrations 
in DPP4null rats preserved the ability to mobilize BM progenitors. The measure of 
rat intact versus cleaved SDF-1α is challenging because traditional sandwich 
ELISA poorly discriminate between the two forms. However, proof-of-concept 
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mass spectrometry analysis of mouse tissues confirmed that absence of DPP-4 
reduces cleavage of native SDF-1α (62). 
Differently from the post-ischemic assay, DPP-4 deficiency did not restore G-CSF 
induced HSC and EPC mobilization in diabetes, confirming data obtained in non-
diabetic Dpp4-/- mice (64). The mobilizing effect of G-CSF relies on the 
establishment of a SDF-1α chemotactic gradient towards the vasculature, by 
reducing intra-marrow concentrations of SDF-1α, through DPP-4 induction and 
suppression of stromal cell activity. We now report that diabetes reduces BM 
DPP-4 activity, which was not stimulated by G-CSF, likely leading to high intra-
marrow SDF-1α levels, a retention signal for stem cells. This is consistent with 
the previous observation of a failed SDF-1α switch in the BM in response to 
tissue injury in diabetes (33). Indeed, while DPP-4 deficiency restored the 
peripheral signal from the ischemic tissue to the BM, response to G-CSF 
remained deficient. Altogether these data indicate that tissue-specific DPP-4 
dysregulation accounts for both defective post-ischemic and G-CSF induced 
mobilization (Figure 16). Recently, it has been demonstrated that DPP-4 
negatively regulates CSF activity and stress hematopoiesis (68). Indeed, several 
CSF types, including native G-CSF, GM-CSF, erythropoietin, and IL-3 appear to 
be substrates of DPP-4 enzymatic activity (68). Cleavage of CSFs by DPP-4 
reduces their biological activities and generates natural competitive inhibitors of 
receptor activation. DPP-4 inhibition or genetic deletion improved hematopoietic 
responses to stressing conditions, such as chemotherapy or radiation. Given that 
diabetic patients suffer from anemia and delayed recovery after myeloablation 
(8), DPP-4 inhibition holds clinical promise also in the setting of stressful 
conditions to which diabetic patients may be exposed. Mechanistically based on 
these data, as G-CSF induces DPP-4 and DPP-4 in turn cleaves G-CSF, this 
appears to be a negative feedback loop regulation of the balance between 
mobilization and engraftment of stem cells. Interestingly however, DPP-4 is not 
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able to cleave methionylated CSF such as hrG-CSF (Filgrastim), explaining why 
DPP-4 deficient rats are still not susceptible to G-CSF induced mobilization. A 
disruption of this mechanism in diabetes may have profound clinical implications 
for homeostasis of the hematopoietic system and its cross-talk with 
cardiovascular biology. 
To sum up, we have conducted a reverse translational study that stems from the 
observation of the clinical phenotype in patients with disturbed progenitor cell 
mobilization and leads to the discovery of a central role for DPP-4 in the diabetic 
stem cell mobilopathy.  
In this clinical data-driven discovery approach for regenerative medicine, we used 
a targeted strategy to screen soluble factors potentially involved in progenitor cell 
regulation, but future development into the human plasma proteome analysis 
may allow an unbiased approach.  
The tissue specific regulation of DPP-4 in diabetes sheds light on the different 
mechanisms of ischemia- and GCSF-induced mobilization and has therapeutic 
implications based on clinically available DPP-4 inhibitors (63). 
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CONCLUSIONS 
 
The 3 substudies presented here constitute a unique investigation into 
bone marrow function in clinical and experimental diabetes. Using very 
different methodological approaches, each substudy clearly shows that 
diabetes leads to an impairment in bone marrow stem/progenitor cell 
mobilization. This was apparent from a prospective clinical trial of direct 
bone marrow stimulation with human recombinant G-CSF in diabetic and 
control patients (Part 1), as well as from a meta-regression analysis of 
clinical trials using G-CSF to stimulate cardiovascular repair in patients 
with different forms of cardiovascular disease. Further, by analysing 
coupled bone marrow and peripheral blood samples of healthy and 
diseased patients in Part 3, an altered distribution of stem cells between 
these two compartments was noted in diabetic patients. In Part 1, initial 
mechanistic data were also provided, by showing a maladaptive DPP-4 
response to G-CSF in diabetic patients. This was further confirmed in Part 
3, where a correlation between DPP-4 activity and stem cell 
compartmentalization was noted. In the pre-clinical substudy of Part 3, a 
tissue specific dysregulation of DPP-4 in diabetic animals emerged as 
responsible for the defective G-CSF-induced and post-ischemic 
stem/progenitor cell mobilization. The clinically-relevant counterpart of 
these observations is that DPP-4 deletion restored ischemia-induced 
mobilization and improved tissue recovery after ischemic damage. 
Altogether, these data point to the existence of a primary bone marrow 
defect in diabetes, which has important implications for the development of 
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chronic complications and can be countered by modulation of DPP-4 
activity. The translation of these findings into clinical practice may turn out 
to be life saving in diabetic patients. 
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Characteristic 
All DM 
subjects 
All non DM 
subjects 
p T1D 
Age-matched 
controls 
p T2D 
Age-matched 
controls 
p 
Number 24 14 - 10 8 - 14 6 - 
Age, yrs 48.8±2.5 40.1±3.8 0.06 37.1±2.6 29.4±2.3 0.06 57.1±1.6 54.5±2.7 0.39 
Sex male, n (%) 20 (83.3) 11 (78.6) 0.73 8 (80.0) 6 (75.0) 0.81 12 (85.7) 5 (83.3) 0.89 
Body mass index, kg/m2 28.0±1.2 25.8±1.3 0.26 25.7±1.0 24.3±1.9 0.49 29.6±1.9 27.5±1.6 0.51 
HbA1c, % 7.9±0.3 - - 7.7±0.3 - - 8.0±0.4 - - 
Plasma glucose, mg/dL 151.3±7.8 84.2±3.1 <0.01 148.2±6.3 80.9±3.6 <0.01 155.7±8.1 89.3±7.4 <0.01 
Serum creatinine, µmol/L 78.2±6.5 81.3±3.4 0.65 77.4±5.4 78.2±3.8 0.88 84.3±4.5 83.7±2.9 0.89 
Diabetes duration, yrs 16.1±2.3 - - 21.2±3.1 - - 12.5±2.9* - - 
Hypertension, n (%) 15 (62.5) 2 (14.3) 0.01  2 (20.0) 0 (0.0) 0.56 13 (92.8)* 2 (33.3) 0.03 
Complications          
Cardiovascular disease, n (%) 6 (25.0) 0 (0.0) 0.10 0 (0.0) 0 (0.0) - 6 (42.9)* 0 (0.0) 0.07 
Retinopathy, n (%) 8 (33.3) - - 5 (50.0) - - 3 (21.4) - - 
Nephropathy, n (%) 2 (8.3) - - 1 (10.0) - - 1 (7.1) - - 
Neuropathy, n (%) 6 (25.0) - - 3 (30.0) - - 3 (21.4) - - 
Medications          
Insulin, n (%) 20 (83.3) - - 10 (100) - - 10 (77.0) - - 
Oral anti-diabetic agents, n (%) 11 (43.8) - - 0 (0.0) - - 11 (78.6)* - - 
ACE-inhibitors, n (%) 13 (54.2) 1 (7.1) 0.01 3 (30.0) 0 (0.0) 0.29 10 (77.0) 1 (16.7) 0.03 
Other anti-hypertensives, n (%) 9 (37.5) 0 (0.0) <0.01 2 (20.0) 0 (0.0) 0.56 7 (50.0) 0 (0.0) 0.05 
Statins, n (%) 12 (50.0) 0 (0.0) <0.01 2 (20.0) 0 (0.0) 0.56 10 (77.0)* 0 (0.0) <0.01 
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Table 2. Hematological parameters and absolute progenitor cell counts in DM 
and non DM patients before and after administration of hrG-CSF in Part 1. 
*p<0.05 versus baseline. 
 
Variable 
Diabetic patients (n=24) Non diabetic subjects (n=14) 
Baseline 
Post hrG-
CSF 
Baseline Post hrG-CSF 
White blood cells x 10
3
 / 
µL 
6.53±0.32 21.88±0.82* 6.05±0.34 23.54±1.14* 
Neutrophils x 10
3
 / µL 3.57±0.26 17.91±0.74* 3.29±0.22 19.94±0.97* 
Lymphocytes x 10
3
 / µL 2.20±0.10 2.60±0.14 2.02±0.12 2.34±0.20 
Monocytes x 10
3
 / µL 0.55±0.03 1.06±0.04* 0.52±0.05 1.00±0.04* 
Eosinophils x 10
3
 / µL 0.18±0.02 0.28±0.03 0.19±0.04 0.27±0.06 
Basophils x 10
3
 / µL 0.03±0.003 0.04±0.004 0.03±0.005 0.04±0.003 
Red blood cells x 10
6
 / µL 4.88±0.07 4.82±0.08 5.04±0.11 4.91±0.12 
Platelets x 10
3
 / µL 235.4±7.5 231.5±8.7 243.0±12.4 237.6±13.1 
CD34
+
 cells / mL 3236±269 3289±269 2837±351 6312±743* 
CD133
+
 cells / mL 1884±185 2128±212 937±184 2476±409* 
CD34
+
CD133
+
 cells / mL 1204±179 1423±193 719±156 2152±374* 
CD34
+
KDR
+
 cells / mL 253±34 223±38 201±46 515±145* 
CD133
+
KDR
+
 cells / mL 287±55 274±40 249±84 754±266* 
CD34
+
CD133
+
KDR
+
 / mL 31±8 27±7 38±11 86±27 
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Table 3. Characteristics of the trials included in the meta-regression analysis in Part 2. Total G-CSF dose is reported in µg/kg. CD34+ cells 
refers to the achieved CD34+ cell count (cells / µL ± standard deviation) at completion of the G-CSF course. N, number of patients. HT, 
hypertension. DL, dyslipidemia. STEMI, ST-elevation myocardial infarction. CLI, critical limb ischemia. CHF, chronic heart failure. IHD, ischemic 
heart disease. IA, intractable angina. * Calculated. † Derived from figures. ‡ reports CD34+CD133+ cell count. N/A, not available. 
 
Authors (ref) 
G-CSF 
dose Days CD34+/µL  N %DM Age %Male %HT %DL %Smokers Disease 
Achilli et al. (69) 50.0 5.0 56.7 ± 61.1 29 20.7 61.0 ± 8.0 100.0 48.0 59.0 59.0 STEMI 
Arai et al. (70) 35.0 10.0 4.7 ± 0.9 14 50.0 69.0 ± 2.0 50.0 N/A N/A N/A CLI 
Boyle et al.  (71) 40.0 4.0 24.3 ± 9.0 5 40.0 65.4 ± N/A 80.0 100.0 100.0 0.0 IHD 
Burt et al. (49) 45.0 4.5 20.2 ± 17.4 9 44.4 68.1 ± 19.3 55.6 77.8 55.6 77.8 CLI 
Chih et al. (72) 22.5 5.0 33.0 ± 8.0† 18 22.2 62.0 ± 7.0 89.0 78.0 83.0 72.0 IHD 
Ellis et al. (A) (73) 25.0 5.0 37.0 ± 30.0 6 16.7 53.0 ± 15.0 100.0 50.0 N/A 40.0 STEMI 
Ellis et al. (B) (73) 50.0 5.0 29.0 ± 14.0 6 33.3 60.0 ± 11.0 83.0 33.0 N/A 50.0 STEMI 
Engelmann et al. (74) 50.0 5.0 46.1 ± 32.9‡ 23 21.7 60.0 ± 11.0 87.0 74.0 57.0 65.0 STEMI 
Huttman et al. (75) 88.6 10.0 20.4 ± 22.4* 16 37.5 61.0 ± 10.0 100.0 56.3 81.3 62.5 CHF 
Ince et al. (76) 60.0 6.0 66.0 ± 54.0 15 13.3 51.1 ± 8.2 93.3 40.0 66.7 80.0 STEMI 
Ince et al. (77) 60.0 6.0 64.6 ± 37.1 25 8.0 50.5 ± 7.9 92.0 40.0 64.0 80.0 STEMI 
Karimabad et al. (78) 50.0 5.0 24.3 ± 8.6 8 50.0 48.6 ± 8.7 87.5 12.5 12.5 62.5 STEMI 
Kluethe et al. (79) 70.0 7.0 75.8 ± 44.6 14 21.4 57.7 ± 11.5 100.0 N/A 35.7 35.7 STEMI 
Kovacic et al. (80) 50.0 5.0 100.0 ± 17.0† 20 15.0 62.4 ± 9.1 90.0 90.0 100.0 0.0 IA 
Leone et al. (81) 50.0 5.0 50.3 ± 35.2 14 14.3 53.0 ± 11.0 93.0 57.0 64.0 71.0 STEMI 
Losordo et al. (82) 25.0 5.0 28.7 ± 16.5 24 41.7 62.4 ± 25.0 79.2 77.8 94.4 72.2 IA 
Ripa et al. (83) 60.0 6.0 55.1 ± 53.3 39 7.7 57.4 ± 8.6 72.0 33.0 N/A 56.0 STEMI 
Ripa et al. (84) 60.0 6.0 47.1 ± 8.8 16 43.8 62.0 ± 9.0 87.5 44.0 100.0 13.0 IHD 
Sprigg et al. (85) 50.0 5.0 37.7 ± 36.7 24 29.2 76.0 ± 9.0 50.0 75.0 33.0 N/A Stroke 
Stein et al. (86) 50.0 5.0 72.0 ± 20.0 56 10.7 59.4 ± 12.0 78.6 55.4 41.1 44.6 STEMI 
Suzuki et al. (A) (87) 31.0 10.0 3.9 ± 2.1 11 54.5 63.0 ± 10.0 72.7 81.8 81.8 18.2 IA 
Suzuki et al. (B) (87) 26.0 10.0 9.0 ± 4.7 12 25.0 65.0 ± 9.0 83.3 50.0 33.3 N/A STEMI 
Takano et al. (88) 12.5 5.0 15.0 ± 19.8 18 33.3 61.0 ± 8.0 77.8 44.4 33.3 50.0 STEMI 
Valgimigli et al. (89) 20.0 4.0 33.0 ± 7.0† 10 20.0 62.0 ± 9.0 80.0 60.0 N/A 40.0 STEMI 
Wang et al. (90) 30.0 6.0 22.9 ± 4.0* 13 46.2 63.0 ± 2.0 84.6 N/A 100.0 N/A IHD 
Wolfram et al. (91) 35.0 7.0 33.0 ± 22.8 8 37.5 69.0 ± 10.0 62.5 100.0 N/A N/A IA 
 65
Table 4. Pooled characteristics of the patients from trials included in the primary 
analysis of Part 2 substudy. 
 
 
Characteristic Weighted average 
Number 453 
Age, years (range) 60.7 ± 21.1 (50-76) 
Male sex, % (range) 81.7 (50-100) 
Diabetes, % (range) 24.7 (8-55) 
Hypertension, % (range) 58.0 (13-100) 
Dyslipidemia, % (range) 62.4 (13-100) 
Smoking, % (range) 52.4 (18-80) 
Type of disease  
ST-elevation myocardial infarction, n (%) 275 (60.7) 
Chronic heart failure, n (%) 16 (3.5) 
Ischemic heart disease, n (%) 52 (11.5) 
Intractable angina, n (%) 63 (13.9) 
Stroke, n (%) 24 (5.3) 
Critical limb ischemia, n (%) 23 (5.1) 
Total G-CSF dose, µg/kg (range) 46.6 ± 7.3 (12.5-88.6) 
Treatment duration, days (range) 6.0 ± 1.9 (4-10) 
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Table 5. Multivariable analysis conducted in the n=16 trials reporting data on all 
the covariates (Part 2). The dependent variable was achieved CD34+ cell count. 
 
 
Variable β-coefficient P 
Diabetes mellitus -1.128 0.028 
Mean age 0.158 0.710 
Male gender -0.114 0.731 
Hypertension -0.163 0.726 
Dyslipidemia -0.460 0.384 
Smoke -0.113 0.671 
Underlying disease 0.760 0.176 
Sample size 0.050 0.867 
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Table 6. Characteristics of the study population in Part 3. *p<0.05. 
 
Characteristic Healthy subjects 
(n=12) 
Patients 
(n=60) 
Age (years) 31.3±2.0 58.3±1.8* 
Male sex (%) 40.0 83.3* 
Smoking habit (%) 33.3 25.9 
Obesity (%) 0.0 41.6* 
Family history for CV (%) 0.0 46.6* 
Diabetes mellitus (%) 0.0 28.3* 
Plasma glucose (mg/dL) 81.8±4.1 118.3±7.8* 
Hypertension (%) 0.0 70.7* 
Dyslipidemia (%) 0.0 70.2* 
Total cholesterol 175.6±11.9 174.8±7.0 
HDL cholesterol (mg/dL) 68.9±9.6 48.0±1.9* 
Triglicerydes (mg/dL) 93.6±14.3 164.2±17.3 
LDL cholesterol (mg/dL) 98.5±10.1 91.2±5.5 
Medications   
Statin (%) 0.0 68.9* 
ACE inhibitor /AR blocker (%) 0.0 74.1* 
Beta-blockers (%) 0.0 77.6* 
Other anti-hypertensives (%) 0.0 12.1 
Insulin (%) 0.0 8.6 
Oral anti-diabetic agents (%) 0.0 10.3 
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CD34+ CD133+ CD34+CD133+ CD34+KDR+ CD133+KDR+ CD34+CD133+KDR+
CD34+ 0,43* 0,20 0,29* 0,27* 0,08 0,16
CD133+ 0,45* 0,31* 0,41* 0,20 0,01 0,16
CD34+CD133+ 0,44* 0,30* 0,44* 0,21 0,00 0,20
CD34+KDR+ 0,05 0,13 0,05 0,35* 0,43* 0,42*
CD133+KDR+ 0,06 0,17 0,13 0,30* 0,50* 0,46*
CD34+CD133+KDR+ 0,15 0,20 0,30* 0,19 0,28* 0,37*
Peripheral blood
B
o
n
e
 m
a
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o
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Table 8. Multivariable linear regression analysis for identification of determinants 
of peripheral blood CD34+ cell count (dependent variable) in Part 3. 
 
 
Variable Beta coefficient p value 
Bone marrow CD34+ cells 0.392 0.002 
Age -0.110 0.450 
Diabetes -0.300 0.040 
Hypertension -0.044 0.754 
Obesity -0.032 0.813 
Beta-blocker use 0.171 0.172 
Insulin use 0.349 0.01 
 
 
 
 
 
70
T
a
b
le
 9. C
linical characteristics and prog
enitor cell com
p
artm
entalization in P
art 
3. G
roup 1 “H
ealthy”, g
roup 2 “poor m
obilizers” g
ro
up 3 “g
ood m
obilizers”, g
roup 
4, “exhausted”. 
    
Characteristic CD34+ CD133+ CD34+CD133+ CD34+KDR+ CD133+KDR+ CD34+CD133+KDR+ 
Demographics       
Age NS Lower in group 1 NS Higher in group 
2 
NS NS 
Sex NS NS NS NS NS NS 
Risk factors       
No. risk factors Lower in group 1 Lower in group 1 Lower in group 1 NS NS NS 
Smoke NS NS NS NS NS NS 
Family History NS Higher in group 4 Higher in group 4 NS NS Lower in group 4 
Diabetes Lower in group 1 NS NS NS NS NS 
Hypertension Lower in group 1 Lower in group 1 Lower in group 1 Lower in group 
3 
NS NS 
Dyslipidemia NS NS NS NS NS Lower in group 4 
Obesity Lower in group 1 NS NS NS NS NS 
Medications       
Statins NS Lower in group 1 
Higher in group 2 
NS NS NS NS 
ACEi / ARBs NS NS NS NS NS NS 
Beta-blockers Lower in group 2 
Higher in group 3 
NS NS NS NS NS 
Insulin Higher in group 3 NS NS NS NS NS 
Angiogenic factors       
Angiopoietin-2 NS Higher in group 1 Higher in group 1 NS NS NS 
Follistatin NS NS NS NS NS NS 
G-CSF NS NS NS NS NS NS 
IL-8 NS NS NS NS NS NS 
Leptin NS NS NS NS NS Higher in group 3 
PDGF-BB NS Higher in group 1 Higher in group 1 NS NS NS 
PECAM-1 NS NS NS NS NS NS 
VEGF Lower in group 1 NS NS NS NS NS 
SDF-1 NS NS NS NS NS Higher in group 1 and 3 
SCF NS NS NS NS NS NS 
IL-18 NS NS NS NS NS NS 
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Table 10. Body weight, plasma glucose and HbA1c of the four groups of animals 
(Part 3). *p<0.05 versus non diabetic of the same strain. There were no 
significant differences between non diabetic wild type and DPP4null mice and 
between diabetic wild type and DPP4null mice. 
 
 
 
Wild type 
non diabetic 
DPP4null 
non diabetic 
Wild type 
Diabetic 
DPP4 null 
diabetic 
Weight (g) 348±17 338±14 229±14 * 236±7 * 
Plasma glucose (mg/dL) 154±23 120±6 480±42 * 410±22 * 
HbA1c (%) 4.3±0.1 4.5±0.1 12.1±0.7 * 11±1.1 * 
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Figure 1. CD34+ cell mobilization after hrG-CSF. A) Absolute pre- and post-G-
CSF CD34+ cell count in all DM and all non DM controls (study primary end-
point). *p<0.05 versus baseline. B-C) Absolute pre- and post-G-CSF CD34+ cell 
count in type 1 DM compared to young controls (B) and in type 2 DM compared 
to age-matched controls (C). *p<0.05 versus baseline. D) Changes in the 
absolute levels of circulating CD34+ cell counts. *p<0.05 versus DM.  
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Figure 2. Mobilization of other progenitor cell phenotypes after hrG-CSF. A-
E) Absolute pre- and post-G-CSF cell counts of circulating hematopoietic stem 
cells (CD133+, CD34+CD133+) and endothelial progenitor cells (CD34+KDR+, 
CD133+KDR+ and CD34+CD133+KDR+) in DM and non DM patients. *p<0.05 
versus baseline. F) Changes in the absolute levels of stem/progenitor cell 
phenotypes in DM and non DM patients. *p<0.05 versus non DM controls. 
 
-1000
0
1000
2000
3000
4000
5000
CD
34
+
CD
13
3+
CD
34
+C
D1
33
+
Non Diabetic
Diabetic
C
h
a
n
g
e
 i
n
 c
e
ll
 c
o
u
n
t 
/ 
m
L
-200
-100
0
100
200
300
400
500
600
700
800
900
CD
34
+K
D
R+
CD
13
3+
KD
R+
CD
34
+C
D1
33
+K
DR
+
0
500
1000
1500
2000
2500
3000
             Pre               Post             Pre               Post 
                Non diabetic                      Diabetic
C
D
3
4
+
1
3
3
+  
ce
ll
s/
 m
L
0
500
1000
1500
2000
2500
3000
3500
             Pre               Post             Pre               Post 
                Non diabetic                      Diabetic
C
D
1
3
3
+
 c
e
ll
s/
 m
L
* *
*
A
D
B C
E F
* * * *
0
100
200
300
400
500
600
700
             Pre               Post             Pre               Post 
                Non diabetic                      Diabetic
C
D
3
4
+ K
D
R
+  
ce
ll
s/
 m
L
*
0
200
400
600
800
1000
1200
             Pre               Post             Pre               Post 
                Non diabetic                      Diabetic
C
D
1
3
3
+
K
D
R
+  
ce
ll
s/
 m
L
0
20
40
60
80
100
120
             Pre               Post             Pre               Post 
                Non diabetic                      Diabetic
C
D
3
4
+ C
D
1
3
3
+ K
D
R
+  
ce
ll
s/
 m
L
*
 
 
 74
Figure 3. Effects of hrG-CSF on CD26/DPP-4 expression. Percentage 
CD26/DPP-4 expression on CD34+ cells was significantly (*p<0.05) increased in 
non DM controls, while it was reduced in DM patients.   
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Figure 4. In vivo proangiogenic cell function. Patients’ PBMC before collected 
pre- and post-GCSF were embedded into Matrigel plugs and implanted in 
immunodeficient mice. Representative gross appearance of the plugs (scale bar 
= 1 cm) and histological sections (scale bar 100 micron) are shown. In the 
bottom, quantification of hemoglobin content, a quantitative surrogate of 
perfusion, adjusted for mobilized monocytes, is shown. *p<0.05 versus pre-
GCSF; † p<0.05 versus non DM. 
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Figure 5. Pre- and post-G-CSF levels of white blood cells (WBC, A), neutrophils 
(B) and monocytes (C) count in DM and non DM patients. * p<0.05 versus pre-
GCSF. D) Absolute changes in WBC, neurophils and monocytes: no significant 
differences were found between DM patients and non DM controls in the change 
in blood cell counts. 
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Figure 6. Significant linear correlations between Matrigel plug neovascularisation 
and progenitor cell levels. White circles indicate pre-GCSF; black circles indicate 
post-GCSF data. 
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Figure 7. The PRISMA flow diagram illustrating the phases of data selection. 
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Figure 8. The itemized methodological quality graph. For each item, trials are 
scored as low risk of bias (complies with the item), uncertain risk of bias (not 
reported) or high risk of bias (does not comply with the item). The percentages of 
trials with low, uncertain and high risk of bias are plotted. 
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Figure 9. Plots illustrating the meta-regression between prevalence of diabetes 
(explanatory variable) and achieved (A) or increase (B) in absolute CD34+ cell 
count. Each circle represents a clinical trial included in the analysis. The area of 
the circles are proportional to weights of the studies. The regression line is shown 
with 95% confidence intervals (dashed lines). 
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Figure 10. Most circulating CD34+ cells are viable, non-proliferating and 
bone marrow-derived. A) Correlation between bone marrow and peripheral 
blood CD34+ cell counts. Dashed lines indicate the 95% C.I. of the regression 
line. B) Fluorescence in situ hybridization (FISH) analysis of circulating CD34+ 
cell origin. The upper panels show positive controls of male cells (hybridization 
efficiency). The lower panels show Y-chromosome signal in sorted circulating 
CD34+ cells from females transplanted with a male bone marrow (zoom from 40x 
original magnification). The table summarizes the percentage of chimerism of 3 
transplanted patients, after correcting for the Y-chromosome hybridization 
efficiency. C) Circulating CD34+ cells were analyzed for DNA content: the CD34 
vs PI plot shows very few CD34+ cells above the PI threshold for the G2-M 
phase. The proliferating rate of 3 replicates is shown. D) Apoptosis of circulating 
CD34+ cells: the CD34 vs Annexin-V plot shows that very few CD34+ cells 
stained positive for the early apoptotic marker Annexin-V. The apoptotic rate of 6 
replicates is shown. 
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Figure 11. Stem cell compartmentalization and the cardiovascular risk 
profile. Patients were divided into 4 groups according to their circulating and 
bone marrow CD34+ cell counts. Cut-offs for definition of groups were based on 
the 40° and 60° percentile of the distribution. Relevant clinical characteristics of 
the patients in each group are shown. *p<0.05 in post-hoc test versus the 
exhausted group after ANOVA or Kruskall-Wallis, as appropriate. 
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Figure 12. Self-organizing maps showing clinical phenotypes associated 
with stem cell compartmentalization. A) Self-organizing maps colouring of 
clinical features in patients analyzed for stem cell compartmentalization. The 
colour scale indicates deviation from the population mean compared to random 
fluctuations that can be expected by chance. Numbers on selected hexagons 
indicate the prevalence (from 0 to 1) or the mean of each variable for that region. 
The p-values indicate the probability to observe equal colour distribution from 
random fluctuations. B) Topological localization of stem cell compartmentalization 
groups can be visually overlaid to maps in panel A to derive a representation of 
the clinical typical phenotype of each group. C) Each histogram of this figure 
represents a multivariate clinical profile in which bars can be interpreted as 
regression coefficients. The topological organization is the same as in the maps 
of panels A and B. Thus, bar plots illustrate the averaged profile for patients that 
reside on a given hexagon. The legends aids interpretation of the histograms: for 
instance, the upper-right region contains a typical patient with advanced age, 
diabetes, hypertension and obesity, belonging to the “exhausted” group. D) 
Typical phenotypes associated with stem cell compartmentalization groups are 
shown. Numbers in the hexagons represent sample size. The analysis was 
conducted in the whole cohort of 72 patient. 
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Figure 13. DPP-4 activity in diabetic and non diabetic animals. DPP-4 activity 
was measured in plasma and BM extracts of diabetic and non diabetic F344 rats. 
BM samples were also collected at the end of G-CSF stimulation. *p<0.05. 
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Figure 14. DPP-4 deficiency does not restore the defective G-CSF response 
in diabetic rats. The levels of circulating Sca-1+c-kit+ and Sca-1+CD31+ 
progenitor cells were determined by FACS at baseline, and after 5 day 
administration of G-CSF. A) The gating strategy used to enumerate Sca-1+c-kit+ 
and Sca-1+CD31+ cells. Data from a representative wild type (WT) non diabetic 
animal are shown. B) Effects of G-CSF on circulating Sca-1+c-kit+ and Sca-
1+CD31+ cells in WT and DPP4null diabetic and non diabetic (control) rats. * 
p<0.05 post- vs. pre-G-CSF. Bars indicate SEM. Logarithmic scale. 
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Figure 15. DPP-4 deficiency restores post-ischemic progenitor cell 
mobilization in diabetic rats. The levels of circulating Sca-1+c-kit+ and Sca-
1+CD31+ progenitor cells were determined at baseline, day 3 and day 7 after 
hind limb ischemia. A) The gating strategy used to enumerate Sca-1+c-kit+ and 
Sca-1+CD31+ cells is shown on the left. Data from a representative wild type 
(WT) non diabetic animal are shown. Trends over time of circulating Sca-1+c-kit+ 
and Sca-1+CD31+ cells in WT and DPP4null diabetic and non diabetic (control) 
rats are shown on the right. * p<0.05 diabetic vs. controls. Bars indicate SEM. B) 
Capillary density in ischemic muscles at day 7 in wild type and DPP4null diabetic 
and non diabetic rats. Capillaries are stained in green with lectin (40x).  C) 
Degree of ischemia assessed by staining with the hypoxia marker pimonidazole. 
Pimonidazole adducts formed in tissue areas with pO2<10 mmHg were detected 
by immunohistochemistry *p<0.05 diabetic vs. non diabetic. 
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Figure 16. The role of DPP-4 in diabetic stem cell mobilopathy. Bone marrow 
stem cell mobilization is governed by SDF-1α gradients across the 
osteoblast/mesenchymal compartment and the vasculature within the niche. In 
the non diabetic condition, tissue ischemia upregulates circulating SDF-1α, which 
is partly cleaved by DPP-4. G-CSF activates bone marrow DPP-4 and reduces 
SDF-1α. As a result, both stimuli create a mobilizing gradient toward the 
vasculature. In diabetes, circulating DPP-4 activity in increased and ischemia-
derived SDF-1α is reduced, thereby impairing post-ischemic mobilization. In 
addition, diabetes reduces DPP-4 activity in the bone marrow and prevents G-
CSF from suppressing SDF-1α concentrations. Thus, tissue specific DPP-4 
maladaptation in diabetes is responsible for both G-CSF and ischemia-induced 
impaired mobilization. DPP-4 deficiency in diabetes protects circulating SDF-1α 
from degradation and restores post-ischemic mobilization, but not G-CSF 
induced mobilization, which requires stimulation of DPP-4. 
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Figure 17. Self-organizing maps showing clinical phenotypes associated 
with stem cell compartmentalization. A) Self-organizing maps colouring of 
clinical features in patients analyzed for stem cell compartmentalization. The 
colour scale indicate the deviation from the population mean compared to 
random fluctuations that can be expected by chance. The numbers on selected 
hexagons indicate the prevalence (from 0 to 1) or the mean of each variable for 
that region. The p-values indicate the probability to observe equal colour 
distribution from random fluctuations. B) The topological localization of stem cell 
compartmentalization groups can be visually overlaid to maps in panel A to 
derive a representation of the clinical typical phenotype of each group. C) Each 
histogram of this figure represents a multivariate clinical profile in which bars can 
be interpreted as regression coefficients. The topological organization is the 
same as in the maps of panels A and B. Thus, bar plots illustrate the averaged 
profile for patients that reside on a given hexagon. The legends aids 
interpretation of the histograms: for instance, the bottom-right region contains a 
typical patient with advanced age, diabetes, hypertension and obesity, belonging 
to the “exhausted” group. D) The typical phenotypes associated with stem cell 
compartmentalization groups are shown. Numbers in the hexagons represent 
sample size. The analysis was conducted in the subgroup of patients defined by 
the 40°/60° percentile partitioning. 
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Figure 18. Self-organizing maps showing the co-localization of high DPP-4 
activity with CD34+ cell compartmentalization. The right panel shows self-
organizing maps colouring of the patients’ CD34+ cell mobilizer phenotype. The 
left panel shows the corresponding SOM for DPP-4 activity, which clearly 
indicates co-localization of high DPP-4 activity with the exhausted phenotype and 
of low DPP-4 activity with the healthy phenotype. 
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Figure 19. Assessment of skin blood flow after ischemia. Laser Doppler 
Imaging was used to determine superficial skin blood flow at day 7 after ischemia 
in diabetic and non diabetic, wild type and DPP-4null rats. Both limbs were 
monitored and the ischemic/non ischemic ratio is reported. There was no 
significant difference among groups in skin perfusion 7 days after femoral artery 
and vein excision, although diabetic rats tended to have a lower perfusion ratio. 
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Figure 20. Apoptosis in muscle tissue. Apoptosis was evaluated with the in 
situ TUNEL method (ApopTag) in ischemic and non ischemic muscle sections of 
diabetic and non diabetic, wild type and DPP-4null rats at day 7 after induction of 
ischemia. Nuclei were stained in blue with Hoechst, the basement membrane 
was stained in green with laminin and apoptotic cells were stained in red. 
The average number of apoptotic cells per section was very low and most 
apoptotic cells were located in the interstitium (see inserts). There was a non 
significant trend toward reduced apoptotic cell number in DPP-4null rats.  
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